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 Developing effective high throughput screening (HTS) methods is of paramount 
importance in the early stage of drug discovery. When a protein binding event can be 
detected via spectroscopy, then absorbance, fluorescence or chemiluminescence based 
assays can be used to screen for tens of thousands of compounds per day. However, this 
is not feasible for many protein targets. To screen for drug candidates for target proteins 
where standard light based assays are not viable, we developed a high throughput 
screening method using LC-MS. Our assay is label free, which allows for rapid assay 
development and eliminates the risk of label interfering with the drug-protein complex. 
The main challenge of MS based screening methods is the high rate of false positives; 
our MS based screening method identifies binding partners for a target protein with no 
detection of false positives. In this method, ligands are mixed with the immobilized target 
protein and the non-binding analytes are detected, binding lignads are identified by 
comparing with a control where no protein was added.  The tightest binders completely 
disappear from the ligand sea after the protein is added, therefore, these high affinity 
ligands are readily detected as peaks that are absent in the MS data. We then extended 
our study to eliminate not only the false positives but also the false negatives under high 
throughput conditions. The assay, which is similar to a ligand fishing experiment, 
mitigates false positives by selectively identifying positive hits when a ligand at the binding 
site of interest is displaced. The reporter molecule ionizes well, eliminating false negatives 
caused by non-ionizing compounds. Finally, we further extended our study to develop 
MS-based HTS assay using minute amount of target proteins to identify weak affinity 
ligands while still mitigating false positives and negatives. In summary, this dissertation 
addresses the major challenges in the field of MS-based HTS to identify binders for target 
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proteins with no false positives or negatives. These improvements meet the current 
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Chapter 1: Mass spectrometry based high throughput screening methods for 




 Finding an inhibitor for a target protein of interest by screening millions of 
compounds has a high statistical probability. Currently, there is an enormous increase in 
the number of therapeutic targets and the number of massive compound libraries being 
created from combinatorial and parallel synthesis techniques. Therefore, high throughput 
screening (HTS) is an increasingly popular technique in the early drug screening process, 
since it drastically decreases the time needed to find a lead compound for a particular 
target out of millions of potential compounds. However, there are several important 
factors that have to be considered in developing an assay for HTS: relevance, 
effectiveness, speed, robustness, accuracy, and reproducibility.1 Relevance is the 
validation of the screen with a standard or a known compound that has proven successful 
in animal and human model systems. An effective assay minimizes the number of 
compounds identified by the screen and avoids the need for counter screens.  Normally, 
speed is necessary to reduce screening time and to test compounds with diverse 
chemistry or functionality. However, a faster assay is often achieved at the expense of 
accuracy, which can result in lower productivity. Additionally, a HTS assay should be 
pertinent to different classes of chemical compounds. This is known as the robustness of 
an assay. Accuracy and reproducibility measure the lack of false positives and negatives 
without the need to re-assaying several times for discovery of a hit with excellent efficacy.  
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Moreover, an effective assay is faster because different compounds are assayed in the 
same run/batch, instead of in repeated runs. Therefore, developing an assay that 
optimizes all these factors is vital and not trivial. 
The most commonly used HTS assays use florescence and radiometric detection 
,2 owing to the fast detection, simplicity, and miniaturizing ability of these techniques. 
However, developing an HTS assay for a particular therapeutic target can be time-
consuming or impossible, as there is a need to synthesize and modify new compounds 
or tagged compounds to the target or in library compounds in order to obtain a sensitive 
florescence or radiometric signal upon ligand binding.3 Moreover, use of a tagged 
compound on the target could alter the binding of a ligand, resulting in false positives or 
false negatives. Surface plasmon resonance (SPR) and nuclear magnetic resonance 
(NMR) are alternative spectroscopic techniques that are label free, with no alteration of 
ligand binding to the target protein. However, both SPR and NMR are not suitable for 
HTS due to the intense effort required for these techniques. Mass spectrometry (MS) 
based assays are, on the other hand, label free, have fast detection, are able to disclose 
structural information, and are highly selective and sensitive. In addition, MS can 
simultaneously differentiate between the multiple components of a complex reaction 
mixture. These advantages make MS a more appropriate candidate for developing an 
assay to screen ligands for target proteins without the time-consuming development of 
procedures of spectroscopic techniques. Several MS based techniques have been 
developed over the decades, in combination with or without multidimensional 
chromatography, to screen for ligands for target proteins. 
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 The application of mass spectrometry to high throughput ligand screening has 
developed over the last 25 years. The advances in MS-based HTS methods originated 
with new developments in instrumentation and techniques. The purpose of this chapter 
is to discuss the principles, applications, advantages and disadvantages of MS-based 
techniques in early drug discovery. In addition, our aim is to provide information for 
researchers to develop novel techniques with increased functional benefits or apply the 
available techniques to new applications. 
1.1.1 Different MS based techniques for drug screening 
 
MS-based HTS techniques can be divided into two categories: functional based 
and affinity based screening. Functional based screenings consist of three major 
methods. These are MALDI-TOF, SAMDI, and Rapid fire-MS. Affinity based screening 
can be classified into two major categories based whether the protein is immobilized on 
a solid support. In this chapter, we categorize each technique based on the principle that 
the screening method employs.  
1.2 Functional based screening – Enzymatic assay/MS 
 
  In these methods, an enzymatic reaction is used to screen for compounds that can 
regulate or inhibit enzyme activity. These techniques can be used to detect the 
formation of product or the disappearance of substrate during a target enzyme/substrate 
reaction. The assays tend to be very rapid and are easily automated. The ability to 
simultaneously monitor different species by MS has made this screening approach an 
attractive platform for HTS, compared to optical-based assays. The following section 
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discusses different MS-based platforms’ ability, with or without chromatographic 
separation, to identify ligands that modulate the activity of enzyme targets.  
1.2.1 Matrix-assisted laser desorption ionization time-of-flight mass spectrometry 
(MALDI-TOF-MS) 
 
 The most common non-chromatographic MS-based technique is matrix-assisted 
laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF-MS). The 
MALDI-TOF approach provides several advantages:4  fast analysis, consumption of 
minute amounts of sample, high sensitivity, and the possibility of automation.5 Sample 
analytes are mixed and co-crystallized with an easily volatilized matrix and, after 
deposition on an appropriate MALDI plate, are irradiated with a laser. The resulting plume 
produces molecular ions from the sample, which are then detected by TOF-MS. The 
success of this ionization depends heavily on the choice of the matrix compound used for 
co-crystallization. The compound must be volatile, low weight, and able to absorb UV 
more efficiently than the analyte of interest (effectively, matrix molecules should contain 
highly conjugated π systems). It must also be polar and contain acidic protons that will be 
transferred to the analyte molecules to produce molecular ions. Apart from proton 
transfer, the matrix should not directly or indirectly structurally affect the target analyte, 




Figure 1: MALDI-TOF MS profiles for the enzyme reaction for cAMP-dependent Protein 
Kinase, catalytic subunit (PKA). Upper panel: Peptide substrate (kemptide) with buffer, 
without the enzyme. Lower panel: Peptide substrates incubated with the enzyme for 30 
min. This reaction converts a portion of substrate to the expected phosphorylated 
product.6 
Monitoring the conversion of substrate to product by MALDI-TOF-MS has been 
used over the last few decades to identify inhibitors of various target enzymes4, 6-7 As 
early as 1998, Hsieh et al.,4 developed a high throughput bioanalytical method to screen 
small molecule libraries using only picoliter to nanoliter quantities of samples, allowing 
the screening of 4000 samples on a single MALDI plate. Three enzyme targets: 
angiotensin converting enzyme (ACE), N-myristoyltransferase (NMT), and protein 
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tyrosine phosphatase (PTPase) were used in screening for inhibitors. Three separate 
substrates of the target enzymes were used to monitor enzyme activity to identify possible 
inhibitors. The conversion of angiotensin I (m/z 1296.98) to angiotensin II (m/z 1046.52) 
for ACE, NMT substrate when combined with myristoyl-CoA (m/z 801.35 to m/z 1011.59), 
and PTPase substrate (m/z 1702.88 to m/z 1622.85) were used as the reaction indicators.  
MALDI-TOF has been used to identify inhibitors and produce IC50 curves for many 
different classes of target enzymes, including kinases,8 hydroxylases,4 oxygenases,9 
histone demethylases, and acetylcholinesterases7. Due to its simplicity, fast detection 
ability and improved screening throughput of compound/protein interactions, MALDI-TOF 
has gained significant attention in the past decades. Figure 1 shows the MALDI-TOF-MS 
profiles of the enzyme reaction for cAMP-dependent Protein Kinase, catalytic subunit 
(PKA). The profiles clearly show the generation of product from the substrate only in the 
presence of the enzyme PKA.10 Moreover, MALDI-TOF–MS has been successfully used 
to monitor and screen enzymatic activities of multiplexed target proteins to identify 
inhibitors from molecular libraries. With the multiplexing ability of MS, MALDI-TOF 
becomes a useful technique in drug screening analysis. MALDI-MS has been used to 
screen small molecules,11-13 peptides,14-16 proteins,17-19 and polymers.20-22 For example, 
Figure 2 represents MALDI-TOF-MS profiles for enzymatic activity of 
acetylcholinesterase, where the acetylcholine substrate is converted to choline, in the 
presence and absence of the active inhibitor compound. In the presence of an active 




Figure 2: Upper panel: Typical mass spectrum for enzymatic hydrolysis reaction of 
acetylcholine to choline in the presence of acetylcholinesterase inactive inhibitor. Under 
these conditions, the reaction would proceed completely. Lower panel: Typical mass 
spectrum for the same enzymatic hydrolysis reaction in the presence of 
acetylcholinesterase active inhibitor. Under these conditions, the reaction would be 
incomplete.23 
MALDI-TOF suffers from a few notable limitations. One major disadvantage is its 
poor quantification ability. This occurs due the inhomogeneous sample preparation, i.e. 
due to the nature of the spotting matrix and sample droplets causing not only poor sample-
to-sample reproducibility but also poor laser shot-to-shot reproducibility. This problem can 
be minimized, to a certain extent, with the use of an internal standard23-24 optimized 
measurement protocol25-26 and sample preparation procedures that improve 
homogeneity.27 However, finding or synthesizing an appropriate internal standard for the 
monitored substrate can be challenging, which is a problem also shared with all other 
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quantification methods. Though MALDI-TOF-MS based enzymatic methods have an 
edge over spectroscopic methods due to the ability to identify inhibitors in a label free 
manner, this same quality can be shown to be a disadvantage. Failure to find screening-
compatible enzymatic activity for the target enzyme can decrease MALDI-TOF’s 
usefulness in HTS. Even when an assay is available, MALDI-based techniques are limited 
by the same requirements as all other MS methods. Mainly, the analyte of interest must 
be detectable as a gas phase ion. Also, multiple analytes in complex samples compete 
for ionization. Their differential ionization efficiency may result in an inaccurate 
observation of their relative abundances.28 Another major limitation of MALDI-TOF is 
matrix interference, caused by the ample ionization of matrix molecules, which are more 
concentrated, compared to the analyte, in the sample. This leads to saturation of the MS 
detector and suppression of the analyte signal. This problem can be treated by cutting off 
the m/z range if the m/z of the analyte of interest is higher than that of the matrix ions.  
1.2.2 Self-assembled monolayer desorption ionization (SAMDI)-MS 
 
Another new technique, called self-assembled monolayer desorption ionization 
(SAMDI)-MS, has recently emerged in the field. In this technique, the substrate is 
immobilized onto a gold-plated surface via maleimide-terminated self-assembled 
monolayers using thiol groups. Then, the enzyme and the library compounds are 
incubated with the immobilized substrate. Finally, the plates are rinsed and the monolayer 
is irradiated with a laser, resulting in cleavage of the thiolate gold bond and efficient 
desorption and ionization of the chains, which are then analyzed using mass 
spectrometry. Unlike MALDI-TOF-MS, any back ground interferences from salt or matrix 
compounds is not a problem in SAMDI-MS, since the plates are rinsed. Figure 3 is the 
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schematic representation of the SAMDI-MS assay. In this example, the immobilized 
peptide substrate Ac-GRKAcFGC-NH2 was converted to product in the presence of the 
enzyme lysine deacetylase 8 (KDAC8) and  in the absence of an inhibitor compound.29 
Absence and presence of the product after incubation of small molecule libraries is 
assessed in order to identify inhibitors. SAMDI has been used to screen inhibitors for 
many protein targets including methyltransferases,30 nucleic acid ligases,31 kinases,32 
proteases,33 galactosyltransferase,34 lysine deacetylases,35 sirtuin deacetylases,36 and 
phosphatases.37 SAMDI-MS has been developed to screen 105 compounds/day.29 It has 
also been applied to screen enzyme activities in cell lysates37 in  a high throughput 
manner, representing a potential improvement over other available fluorescence-based 
HTS methods.38 Similar to MALDI-MS, poor laser shot-to-shot reproducibility is a 
drawback, not only for quantification, but also for qualitative analysis of certain 






Figure 3: Schematic illustration of a SAMDI assay. Peptide substrates and products are 
covalently bound by the reaction between maleimide-terminated self-assembled 
monolayers and the cysteine thiol group. The thiolate gold bond is cleaved upon laser 
irradiation of the monolayer and the chains are efficiently desorbed and ionized, either 
as disulfides or alkanethiolates. The starting peptide substrate used in the screen 
results in the peak at a mass to charge ratio (m/z) of 1601.3, and the deacetylated 
products are shifted by m/z 42 to a peak at m/z 1559.3.30 
1.2.3 Rapid FireTM mass spectrometry 
 
Another technique that uses the conversion of substrate to product is Rapid FireTM 
mass spectrometry.39 In this method, samples are prepared by mixing target protein, 
substrate, and library of compounds. Next, the samples are quickly run through a small 
column to separate protein complexes from other solution phase components. Then, the 
separated solution phase is sprayed onto a MS for the detection. This technique removes 
any salts, detergents, and buffers through fractionation steps and subsequently supplies 
purified analytes to the mass spectrometer.39 Unlike MALDI and SAMDI-MS, the rapid 
11 
 
fire technique does not use laser irradiation on the samples. Since there is no need for a 
matrix to ionize the analyte of interest, unlike in MALDI and SAMDI-MS, the Rapid Fire 
technique has been successful in addressing reproducibility and ion suppression 
problems associated with MALDI-TOF. In addition, Rapid FireTM still shares important 
benefits, such as salt tolerance and fast detection, with MALDI-TOF. Rapid FireTM uses 
an automated sample collection and purification system that is directly connected to the 
ESI –MS. The Rapid Fire technique, which has the capability of screening ~300 K 
compounds per week,40 has been used to screen for inhibitors of different enzymes, 
including acetylcholinesterases,39 decarboxylases,41 monooxygenase,42 proteases,43 
kinases,44 demethylases,40 and cytochrome p45045 in a high throughput manner.46 
However, this method requires chromatographic or (in most cases) solid state separation, 
which can decrease the sensitivity of the assay due to peak broadening, or loss of 
analytes in the separation cartridge prior to the ionization compared to MALDI-TOF-MS. 
1.3 Affinity based screening 
 
Developing assays to screen for binders of target proteins can be carried out using 
the possible affinity of the target towards small molecules, even if the function or structure 
of the target is unknown.10 In this way, protein binders can be distinguished from the 
remaining unbound compounds. Affinity based screening methods are applicable for wide 
variety of targets. Therefore, developing target protein-specific assays is not necessary, 
as opposed to enzymatic assays. In particular, once an assay is developed for one target, 
it can be applied to screen for ligands of different targets. However, one should be mindful 
of nonspecific binding and MS detection incompatibility. The former can lead to false 
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positive identifications of non-specific binders. The latter reduces confidence in the 
identification of binders that may not be fully ionizable in the MS source. 
In these methods, a protein binder is identified by distinguishing between a sea of 
compounds that remain unbound and the target -bound compounds. The initial step in 
affinity-based screening methods is the formation of a protein-ligand complex. Then, 
detection is performed in one of three ways. First, the bound ligand can be directly 
identified by detection of the protein-ligand complex by MS. Second, the complex can be 
separated from the sea of compounds, followed by identification of the ligand after 
dissociation of the complex. Third, the bound ligand can be identified by comparing the 
unbound compounds with a control sample of library compounds, but without protein 
present.  
Affinity selection methods can be divided into two categories (Figure 4) based upon 
the treatment of the protein of interest. In the first category, the protein is immobilized on 
a solid support. This category can be further classified based on whether the binding 
events occurred online or prior to detection of the ligand involved. Frontal affinity 
chromatography (FAC)-MS is one of the major techniques that uses affinity/binding 
events be online with the detection whereas the HAMS method47 is one of the major 
techniques that uses binding event before the detection. In the second category, the 
protein is not immobilized. This category is divided into two screening techniques: direct 
and indirect screenings. Direct screening involves a homogeneous format where both 
receptor and ligands are in solution. In the direct screening technique, separation of the 
receptor-ligand complexes from the nonbinding compounds takes place inside the MS. 
During indirect screening, other methods of separation are used prior to MS detection. In 
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fact, only the ligand reaches the MS detector. The execution of these techniques, as well 
as their advantages and disadvantages, are discussed in the following section.   
 
Figure 4: Different categories of MS-based affinity selection methods. 
1.4 Techniques with binding event online with the detection 
 
In this category, the target protein is immobilized on a solid support packed inside a 
column. Continuous infusion of the analytes through the column is a key feature of this 
technique. Numerous methods belonging to this category use mass spectrometry to 
identify compounds that bind with a particular target protein. Among those techniques, 
frontal affinity chromatography can be considered as the most commonly used method, 
owing to functionality with very low amounts of target protein.  
1.4.1 Frontal Affinity Chromatography- Mass Spectrometry (FAC-MS) 
 
  Frontal affinity chromatography (FAC)-MS is considered one of the most useful 
techniques among the MS-based affinity chromatography methods.48-50 Figure 5 is a 
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schematic representation of the principles behind FAC-MS.51 This method is carried out 
using a continuous flow of small molecules that pass through an immobilized target 
protein in a column. When small molecules pass by the immobilized target protein, they 
bind to it based on their affinities and finally reach an equilibrium between being 
immobilized on the target protein and continuing to travel in the mobile phase. This 
equilibrium controls their elution from the column. The end point of the experiment is 
determined when the composition of the effluent is equal to that of the influent. The 
compounds are detected by mass spectrometry as they exit the column.48 Since the 
protein ligand binding affinities vary, the effluent volume that passes through the column 
varies to match the concentration of the input ligand. This volume is known as the 
“breakthrough volume” and the higher the affinity of the ligands, the higher the 
breakthrough volume. Breakthrough volumes of analyte compounds are compared with 
that of the void marker, a compound that does not have any affinity to the target protein 
and therefore elutes faster from the column, to estimate the affinity of the analyte 




Figure 5: A schematic diagram showing the principle of FAC–MS. Ligands and a void 
marker are continuously passed through a column containing an immobilized protein.51 
The roll up method is a form of FAC-MS that uses a known binder of a target 
protein as an indicator ion. First, the breakthrough curve for the indicator, demonstrated 
in Figure 5, is obtained. After that, ligand(s) are mixed with the indicator and the 
breakthrough curves for the indicator are collected. As shown in Figure 6, the presence 
of high affinity ligands eluting with the indicator will show a high roll up effect, compared 




Figure 6: Typical FAC–MS indicator responses (roll-ups and shifts)  in screening 
experiments. Purple trace shows the breakthrough front of the indicator in the absence 
of any competing ligands. Magenta trace indicates a ligand that is competitive with the 
indicator, but has a Kd that is weaker than the Kd of the indicator. Such a ligand will 
generate a shift of the indicator’s front to the left. Cyan trace indicates a competitive 
ligand with a Kd that is similar to, or slightly stronger than that of the indicator. This type 
of a ligand will produce a roll-up effect that dominates over the shift of the indicator. 
Stronger competitive binders compared to the indicator will generate significant roll-ups 
for the indicator as shown in green trace.51 
There have been many successful attempts to develop HTS methods with FAC-
MS using libraries with limited number of compounds. Ng et al.52 developed a HTS 
method using a large compound library in which they screened 5000 compounds/day to 
search for inhibitors for N-acetalyglucosamyltransferase. Later, they were able to 
automate the system and demonstrated53 the possibility of screening 10,000 
compounds/day with human estrogen receptor β (hERβ) as the target protein. 
 The FAC-MS method has multiple advantages. This technique is used to rank 
ligands based on their affinity towards the target protein, since low affinity ligands elute 
first and high affinity ligands elute later. Therefore, it is easy to estimate the relative Kd 
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values of different ligands54-55 Use of an indicator ligand in the roll-up method of screening 
provides the opportunity to discriminate between mixtures containing strong binding 
ligands from mixtures with weak binding ligands. Moreover, the roll-up effect helps to 
confirm whether two ligands interact with the same target protein.49  
 Even though FAC-MS possesses many advantages, it has some limitations. The 
requirement of a void marker, time consuming data analysis, and the need for the 
construction of breakthrough curves to identify strong binders impedes the use of this 
method for HTS.51 False negatives, due to buffer compatibility, ion suppression, and the 
limitations of mass resolution power for some instruments are also noteworthy 
limitations.56 Another major drawback arises from immobilization of the target protein. 
Buffer conditions used during immobilization may have an effect on the folding of the 
target protein, influencing the binding of the ligand. In addition, nonspecific binding is 
possible with the linker system and with the stationary phase.51 In summary, even though 
FAC–MS has the limitations mentioned above, it provides valuable information regarding 
the binding events of a ligand to a target protein than MS-based HTS methods with high 
false identification rates. 
1.5 Direct screening technique 
 
 Direct screening can be used to detect both covalent and noncovalent target-ligand 
complexes. This approach is made possible by the soft and tunable ionization process of 
electrospray ionization (ESI). Even though covalent complexes can also be formed via a 
fragment based discovery assembly process,57-58 detection of noncovalent complexes by 
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direct screening is more valuable, since it is a better representation of the target-drug 
interaction.  
In direct screening, bound compounds are identified by directly analyzing the 
protein-bound compounds using ESI-MS. This native MS concept has been used to 
validate both the inter- and intramolecular interactions of proteins59-60 to screen for 
binders 61-62 and to carry out fragment screening.63 Figure 7(i) shows the anticipated mass 
spectrum for direct-screening analysis upon binding of a ligand to a target. Figure 7(ii) 
shows the deconvoluted mass spectra for the binding of an endocellulase mutant, Cel6A 
D117Acd, with various saccharide molecules. The mass difference between the protein 
and the complex increases with increasing mass of the saccharide binding molecules.64 
An instance where direct screening was used successfully to screen for peptide binding 
partners to target proteins was reported by Maaty et.al.65 They have used hydrogen 
exchange mass spectrometry to screen binders for calmodulin and ribonuclease S from 




Figure 7: (i) The expected mass spectrum of the direct ASMS method. The complex 
shows mass shifts upon binding of a ligand. (ii) The deconvoluted mass spectra 
indicating the noncovalent interactions for an endocellulase mutant, Cel6A D117Acd 
(panel A) with the oligosaccharides cellotriose (G3, panel B), cellotetraose (G4, panel 
C), cellopentaose (G5, panel D) and cellohexaose (G6, panel E). The ▼ and ● labels 




 Although very useful, direct screening suffers from several limitations. The mass 
of the protein-ligand complex is not significantly different from the mass of the protein. 
Therefore, it can be difficult to deduce the mass of the ligand, even if there is a binding 
event. As a result, mass spectrometers with high mass accuracy and high resolving 
powers, such as the Orbitrap, Fourier transform ion cyclotron resonance (FTICR), and 
quadrupole time of flight (Q-TOF) mass analyzers, are essential for direct screening. In 
addition, an argument can be made that the structural integrity of the proteins is disturbed 
when the protein is desolvated and transported into the gas phase. Furthermore, full or 
partial alteration of the target-bound compound complex resulting from the ESI process 
cannot be completely eliminated, at least for transient (millimolar to micromolar range) 
binders, as opposed to tight (nanomolar to picomolar range) binders.66 Applying this 
native MS ligand screening technique to a high throughput platform is hindered by certain 
additional limitations. These limitations include the necessity for highly purified and 
concentrated protein samples, the need for keeping the target-bound compound complex 
intact, using a suitable solvent system in ESI-MS, concurrently bringing the complex into 
gaseous phase by desolvation, the requirement for incubation of a small pool or individual 
library compounds with the target to mitigate nonspecific bindings,61 and lastly the time 
consuming data analysis, where spectrum deconvolution is obligatory for obtaining ligand 
information, due to the fact that multiple charge states are often observed.  
1.6 Indirect screening technique   
 
Another incarnation of the affinity selection method that uses non-immobilized 
proteins is the indirect screening technique. This method was developed to circumvent 
certain problems associated with the direct screening method, specifically the need for a 
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solvent system that is compatible with both ESI-MS and ligand-target complexes, need 
for incubation of the individual library compounds with the target (instead of a large pool 
of compounds) to minimize nonspecific bindings, and, finally, time-consuming data 
analysis. In this method, the target protein is first incubated with library compounds. Then, 
the unbound compounds are separated from the complexes (target protein receptor-
ligands), then the bound compounds are released from the target protein and detected 
using MS. 
For efficient separation of unbound compounds from target-ligand complexes, 
ultra-filtration membranes, or size exclusion chromatography (SEC) have been used. 
Figure 8 shows a work flow for a method called “Speed Screen” that has been developed 
using SEC for indirect screening and for which the authors have demonstrated HTS 
capability67-68  A centrifuged 96-well plate assembly of SEC columns with a sample 
loading plate on the top and pinholes at the bottom of each well to collect effluent from 
protein-ligand complexes was used for this approach. Therefore, it was possible to screen 
~ 60,000 compounds per day.69 The speed screen technique has been used to identify 




Figure 8: Major steps in a typical Speed Screen technique (Left) and composition of the 
“Speed Screen sandwich” (Right).70 
Automated ligand identification system (ALIS) has been developed using the SEC-
LC-MS platform for HTS.71-72 The workflow for ALIS is described in Figure 9.72 This 
system is fully automated. In the ALIS process, the target receptor molecule and the 
mixture of compounds are allowed to equilibrate in 96-well plates. Then the unbound 
compounds are separated from the complexes by an SEC column, followed by an 
analytical column. The complexes are monitored by UV detection that is integrated into 
the system.  After detecting the protein (receptor-ligand complex) peak via UV, an 
automatic valve system directs the complex to a reverse phase chromatography column, 
where the complex is desalted and allowed to dissociate. The eluted ligands are then 
detected by MS. ALIS has been used to discover novel inhibitors for protease β-
secretase, a target related to Alzheimer’s disease73 and receptor ligands for orthostatic 
and allosteric muscarinic M2 acetylcholine, G-protein coupled receptors.74-75  ALIS has 
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also been used to study the competitive binding profile of multiple target receptor ligands 
and to evaluate the structure-activity relationship in a single reaction.76 
 
Figure 9: Schematic representation of the ALIS process.72  
An automated, solution-based indirect screening system that displays 
considerable overlap with the ALIS method has been developed by O’Connell et al.77 
using commercially available parts. However, accurate mass analysis gives it a 
substantial edge over ALIS in simplifying hit identifications. Overall, this improved 
technique is capable of screening 1x105 compounds per day with a low hit rate, which is 
indicative of more specific binding and a lower number of false positives.77  
Ultrafiltration membranes have also been used to separate receptor-ligand 
complexes from nonbinding compounds.78-80 First, the target receptor is incubated with a 
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library of compounds. Then the incubation mixture is subjected to centrifugation with 
molecular cutoff filters to separate the unbound compounds from the complex. The bound 
compounds are then released by denaturing the protein/ligand complex. Finally, the 
released compounds are detected using MS. This ultrafiltration-based indirect screening 
method has been used to study the structure and affinity of the human estrogen 
receptors81 and also to identify new inhibitors for MurF, a Streptococcus pneumoniae cell 
wall biosynthesis enzyme.80 
While it is true that affinity based techniques are more compatible with HTS and 
automation, compared to functional based screening, overall they suffer from high rates 
of false positive identification which significantly complicates analysis, though the rate of 
false positive identification varies among the different techniques. Minimizing or 
eliminating false positives and improving upon the existing techniques is of paramount 
importance for the drug development process.    
1.7   Techniques with binding event prior to the detection 
 
In this category, proteins are immobilized on a solid support for use in assays, but 
not packed in a column. Most of the techniques in this category use ligand fishing, where 
a binder is caught from a ligand sea and identified after release. Other techniques involve 
the comparison of unbound compounds in binding experiments with control experiments. 
1.7.1 High Affinity Mass Spectrometry (HAMS) 
HAMS47 is an MS-based high throughput screening method that is used to 
selectively detect binding compounds from complex library mixtures without reporting 
false positives. Figure 6 shows a schematic diagram of the HAMS method. A control 
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experiment, where no protein is used, generates spectra that are compared to binding 
experiment spectra, and the absence of certain peaks is indicative of binding compounds, 
as shown in Figure 10.47 The authors have demonstrated the applicability of HAMS on 
three different target proteins: pepsin, carbonic anhydrase, and maltose binding protein. 
Binders in three affinity ranges (pM, nM and µM) were screened without detecting any 
other compounds as hits, except the known binders for the respective proteins. A 
comparison experiment of the HAMS and Affinity selection mass spectrometry (ASMS)77 
methods was carried out with carbonic anhydrase as the target protein, further confirming 
the lack of false positives in HAMS, whereas a 10% false identification rate was observed 
for ASMS. However, a HAMS experiment is more time consuming, since it necessitates 
acquiring two LC-MS spectra for the same set of compounds, specifically binding and 
control experiments. Similar to all other MS techniques, the HAMS method suffers from 
false negative identifications due mostly to compounds that are not ionizable (and thus 




Figure 10: Schematic diagram of the HAMS method. Inhibitors/binders are incubated 
with the immobilized protein (and, separately, with blocked beads in the control 
experiment), removed, and analyzed by LC-MS. Strong binders were identified by 
comparing the spectral data of the control and binding experiments. The binders are 
present in the data for the control experiment, but absent in the data for the binding 
experiment.47 
Our group recently developed an improved version of the HAMS method, which 
features several advantages over previous methods. The assay can be used to 
selectively identify positive hits when a ligand at the binding site of interest is displaced, 
which lowers the false positives. In this method, a reporter compound that ionizes well, 
rather than the ligand binder which perhaps is a non ionizable compound, is detected. 
This mitigates the appearance of false negatives. In this method, four hundred 
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compounds can be assayed in 10 minutes, demonstrating fast detection, and the assay 
requires low (nanogram) amounts of target protein per compound. In addition, binders 
with Kd’s in the picomolar to micromolar range can be detected by this method. Known 
binders of three proteins, Pepsin, Maltose Binding Protein (MBP), and Carbonic 
Anhydrase (CA), in the presence of hundreds of non-binders were used to validate this 
assay.  Furthermore, a novel CA binder, pifithrin-µ, a compound with poor ionization 
efficiency, which could not have been identified by any other MS-based assay, was also 
identified by this method. 
1.7.2 Additional detection methods 
 
 Ligand fishing is a method originally developed to “fish out” any bioactive 
compounds that bind to a target of interest from sets of natural products.82 In this method, 
activated surfaces are used to immobilize bait molecules and can be carried out either 
online or offline.  In offline analysis, the target protein (the bait) is first immobilized on a 
solid surface, such as resin beads. Then the bait (immobilized protein molecule) is 
immersed in the ligand seas. After that, the immobilized protein is washed thoroughly to 
remove any nonspecifically bound compounds. The specifically bound compounds are 
subsequently released and identified using MS.82 Offline ligand fishing has mainly been 
conducted using magnetic beads or agarose beads coated with biomolecules. Figure 11 
is a schematic representation of offline ligand fishing of active compounds from plant 
extract for a target protein. In this process, protein-coated magnetic beads are incubated 
with the plant extract. After several washing steps, the bound ligand is eluted using an 
organic buffer, and is then identified using MS.82 In an alternative format, where the affinity 
selection is conducted online with the detection step, the immobilized protein is in a 
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column which ligands seas are flowed through. After that, any excess molecules are 
washed out, followed by elution of the bound compound, which is finally identified using 
mass spectrometry. Immobilized enzymes, such as lipases,83 galactosidases,84 
pectinases,85 glucosidases,86 are mostly used to fish out ligands from complex matrixes. 
Even though the applications are promising in the field of drug screening, false positives 
due to non-specific interactions can hinder interpretation of results. 
 
Figure 11: In the ligand fishing approach, protein coated magnetic beads are incubated 
with a plant extract, washed, and then eluted in an aqueous organic buffer. The elution 
buffer is then analyzed by HPLC-MS.82 
High through put screening of drug candidates is a necessity in many drug 
discovery pipelines. When a Mass spectroscopy (MS) based method is used for 
screening, false positive identifications become a major challenge. Chapter 2 describes 
a detection strategy designed to eliminate false positives when screening for the high 
affinity ligands of target proteins. In this approach, the protein is immobilized on a solid 
support and incubated with a library of ligands. Then, the non-binders are separated from 
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the protein-ligand complexes for detection. Binders are identified by comparing MS data 
with a control consisting of a ligand sea to which no target protein was added. Binders 
are not detectable by MS due to being removed with the protein, but readily discernable 
in the control experiment. The assay was demonstrated using three different proteins, 
Pepsin, Maltose Binding Protein (MBP), and Carbonic Anhydrase (CA), with hundreds of 
non-inhibitors. No false positive hits were identified in our approach, as opposed to many 
that were identified in an already reported method.  Our findings demonstrate that the 
approach described here compares favorably to traditional MS based screening methods. 
Chapter 3 introduces a new MS-based HTS assay that possess substantial 
advantages over existing methods. This high throughput assay is designed to identify 
ligands that are able to inhibit non-enzymatic targets. This method is similar to a ligand 
fishing experiment, where a reporter molecule is detected instead of the actual binder. 
Three proteins, Pepsin, Maltose Binding Protein (MBP), and Carbonic Anhydrase (CA), 
in the presence of hundreds of non-binders, were used to validate this method. This new 
method addresses many of the challenges that are encountered by current high 
throughput screening methods. False positives are eliminated by selectively identifying a 
known weak ligand that is displaced from the binding site by a stronger affinity 
counterpart. False negatives are mitigated by detecting the ionizable reporter molecule 
instead of the binding ligand, which may or may not be ionizable. This allows non-
ionizable compounds to be consistently assayed using a MS based method. Four 
hundred compounds can be screened in 10 minutes with this method, using only low 
(nanogram) quantities of target protein per library compound. In addition, a wide variety 
of binders, from the picomolar to micromolar range, can be detected. Moreover, a novel 
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CA binder, pifithrin-µ, which could not have been identified by any other MS-based assay, 
due to its poor ionization efficiency, was identified using this technique. 
Improvements to the method described in Chapter 3 are introduced Chapter 4. We 
developed an assay that reduces the amount of protein needed to screen for micromolar 
binders by 50%.  This is significantly advantageous for a high throughput assay since the 
target protein is often the limiting reagent that influences the number of ligands that can 
be screened at once. Identifying ligands with a Kd in the micromolar range is challenging 
due to their lower affinity, and this is exacerbated when the available quantity of the target 
protein is limited. In this study, our previous ligand fishing HTS assays described in 
Chapter 2, in which 20 µg of protein was used, were re-characterized to identify 
micromolar binders. An internal standard was used to negate non-reproducible detection 
of the reporter molecule for identification of potential binders with a reduced amount of 
target protein, due to the variation of the mass spectrometry ionization source. This novel 
assay mitigates false positives and false negatives in a similar manner to our previous 
methods, in addition to lowering the consumption of proteins. 
Chapter 5 outlines potential future uses of our method. In this chapter, we briefly 
discuss the major barriers for automation and increasing the throughput capability by 
reducing the sample preparation time. Furthermore, the current projects that the 
Desaire group are conducting are also discussed, specifically focusing on screening for 
new inhibitors for protein-protein interaction (PPI). This would be the first assay that 
ever been developed using MS-based high-throughput screening assay to screen for 
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Chapter 2: HAMS:  High-Affinity Mass Spectrometry Screening.  A high-throughput   
screening method for identifying the tightest-binding lead compounds for 
target proteins with no false positive identifications. 
This work has been published by the Journal of the American Society for Mass 
Spectrometry and is reproduced with permission from the journal. 
A major challenge in drug discovery is the identification of high affinity lead 
compounds that bind a particular target protein; these leads are typically identified by high 
throughput screens. Mass spectrometry has become a detection method of choice in drug 
screening assays because the target and the ligand need not be modified.  Label free 
assays are advantageous because they can be developed more rapidly than assays 
requiring labels, and they eliminate the risk of the label interfering with the binding event. 
However, in commonly used MS based screening methods, detection of false positives is 
a major challenge.  Here, we describe a detection strategy designed to eliminate false 
positives. In this approach, the protein and the ligands are incubated together, and the 
non-binders are separated for detection. Hits (protein binders) are not detectable by MS 
after incubation with the protein, but readily identifiable by MS when the target protein is 
not present in the incubation media.  The assay was demonstrated using three different 
proteins and hundreds of non-inhibitors; no false positive hits were identified in any 
experiment.  The assay can be tuned to select for ligands of a particular binding affinity 
by varying the quantity of protein used and the immobilization method.  As examples, the 
method selectively detected inhibitors that have Ki values of 0.2 µM, 50 pM and 700 pM. 
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These findings demonstrate that the approach described here compares favorably to 
traditional MS based screening methods. 
2.1 Introduction 
 
In recent decades, combinatorial and parallel synthesis methods have been 
employed to synthesize millions of library compounds that potentially could be used as 
new therapeutic drugs. One of the vital tasks of drug discovery is fast and effective 
identification of high affinity ligands from libraries containing these vast numbers of 
compounds. When a screening method based on fluorescent1-2 or chemiluminescent3  
read-out is feasible, tens of thousands of compounds can be assayed per day.  Many 
potential drug candidates, however, cannot be probed using these standard assays 
because some druggable interactions, such as protein binding events, cannot be readily 
monitored by a change in fluorescence.  In these cases, assays of lower throughput based 
on Nuclear Magnetic Resonance (NMR) or Surface Plasmon Resonance (SPR) are 
routinely employed.4   
Mass spectrometry (MS) is increasingly used for High Throughput Screening 
(HTS) due to its advantages of fast and sensitive detection, high specificity, and the ability 
to detect compounds without labels.  One of the commonly used MS-based screening 
methods is Affinity Selection Mass Spectrometry (ASMS); this approach probes the 
affinity of various ligands by combining large batches of library compounds with the 
protein of interest and using MS to detect the binding of a small sub-set of those ligands 
to the protein.5-6  In one incarnation of the method, the direct ASMS method, any 
protein/ligand complex that forms is detected directly by MS.  A lead is identified when 
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the mass of the protein is shifted to include the mass of the binding ligand.  The 
disadvantage of this approach is that the ESI process may fully or partially distort the 
protein-ligand complexes; determining appropriate MS parameters for each type of 
complexes is challenging and time consuming. In addition, the mass of the protein/ligand 
complex is not substantially different than that of the protein itself, and even when a 
binding event is detected, it can be difficult to infer the exact mass of the ligand.7  
In another embodiment of the ASMS method, often referred to as “the indirect 
approach,” the binding ligands are identified after the protein-ligand complex is isolated 
and the ligands are dissociated.  This approach has shown to be highly amenable to 
automation, with a throughput of ~ 1*105 compounds per day.8-9 However, it has some 
limiting disadvantages that we seek to address herein.  Namely, the ligands could bind 
weakly and nonspecifically to the protein, and in the ASMS assay, they would still be 
detected as protein binders.8-10 In addition, the method suffers from a higher incidence of 
false positive hits, which can be introduced during the isolation of the ligands from the 
protein complex.  To alleviate this problem, others have used molecular weight cut off 
filters,11 or size exclusion gels12-14 to isolate the protein complexes prior to ligand 
dissociation.  While these approaches are helpful, non-binding ligands may interact with 
these separation media as well, also leading to false positives.  Additionally, these 
solutions do not address the problem of detecting numerous nonspecific and weak 
binders. 
Herein we present a new MS-based high throughput screening assay that shares several 
advantages with the indirect ASMS method described above, but it eliminates several of 
the key disadvantages.  In the approach described here, the protein and ligands are mixed 
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as in the ASMS method, but the non-binding analytes are detected, instead of the binders.  
This detection strategy was chosen to reduce the detection of false positives – those 
compounds that bind weakly or nonspecifically to the protein.  Only the tightest binders 
completely disappear from the ligand sea after protein is added, so those tightest binders 
are readily detected as peaks that are absent in the MS data, when the non-binding 
ligands are analyzed.  The method described herein not only picks out the tightest binding 
ligands, it can also be used to detect ligands with different binding affinities, by tuning the 
concentration of protein used in the assay.  As an additional benefit of screening in this 
manner, the amount of protein required, and the amount of each binding ligand, can be 
substantially reduced compared to the state-of-the-art comparator method.9 Reduction in 
the amount of protein required, in particular, is a strong asset in a high throughput 
screening method; it can substantially reduce assay cost because the quantity of the most 





 The library compounds used in this study are all FDA-approved drugs.  For all the 
experiments conducted with 176 compounds, the drug molecules are selected from the 
Prestwick library, which was obtained from the High Throughput Screening Laboratory at 
the University of Kansas. The library was provided in combined batches of 176 
compounds per vial, dissolved in DMSO at a concentration of 14.2 µM per compound. 
For all the experiments conducted with 352 compounds, the drug molecules were 
obtained from LOPAC1280-small scale library that was purchased from Sigma Aldrich 
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(St. Louis, MO) as individual compounds, dissolved in DMSO at a concentration of 10 
mM per compound. When combining compounds for high throughput screens from the 
LOPAC library, any compound larger than 150 Da was considered a candidate, and no 
effort was made to remove compounds from the library that would likely not ionize by ESI.  
Pepsin, Aminolink plus coupling resin and disposable plastic columns were acquired from 
Pierce Biotechnology, Inc (Rockford, IL), while nitrocellulose drop dialysis membranes 
were purchased from Fisher Scientific (Houston, TX). Maltose binding protein and 
Carbonic Anhydrase were purchased from My BioSource (San Diego, CA) and Sigmal 
Aldrich (Milwaukee, WI), respectively. 
2.2.2 Binding Experiment on agarose. 
 
 Pepsin and Carbonic Anhydrase (CA) immobilization was carried out by adapting 
a procedure published elsewhere.15 The following buffers were used for the binding 
experiment with Pepsin: Citric acid and NaHPO4 (0.1 M, pH 4.5) were used as the 
coupling buffer; the blocking buffer was Tris HCl (1.0 M, pH 4.5); the incubation buffer 
was ammonium acetate (0.02 M, pH 4.0); and the wash buffer was a solution of 1 M NaCl 
in coupling buffer. Similarly, for CA, the coupling buffer was phosphate buffered saline 
(PBS) (0.1 M, pH 7.4); the blocking buffer was Tris HCl (1.0 M, pH 7.4); the incubation 
buffer was ammonium acetate (0.02 M, pH 7.4); and the wash buffer was a solution of 1 
M NaCl in coupling buffer. Both Pepsin and CA were dissolved in 100 µL of coupling 
buffer and were dialyzed for 1 hr with the coupling buffer using a 0.025 mm nitrocellulose 
drop dialysis membrane.  A disposable plastic column was filled with coupling resin and 
washed with 2 mL of coupling buffer. Then, dissolved protein was added (in the amounts 
described below) followed by addition of 1 M NaCNBH4 prepared in coupling buffer, until 
42 
 
the final concentration of NaCNBH4 is 50 mM. The column was rocked overnight and 
washed with 10 mL of coupling buffer followed by 5 mL of blocking buffer. Thereafter, 
1mL of blocking buffer was added followed by 1M NaCNBH4, until the final concentration 
is 50 mM and the mixture was rocked for 2 hrs. Next, the column was washed with 10 mL 
of coupling buffer, 10 mL of wash buffer, and 15 mL of incubation buffer, respectively. 
Finally, the immobilized protein was transferred to Eppendorf tubes for the incubation with 
the library compounds.  
 The quantities of protein used for testing different libraries are as follows: For the 
limited library, 10 mg of Pepsin was immobilized onto 1000 µL of resin beads.  For the 
experiments with larger libraries, significantly less protein was used.  For the 176 
compound library, 450 µg of Pepsin was coupled to 250 µL of resin beads. For the 352 
compound library, initial experiments used,100 µg of Pepsin coupled to 100 µL of resin 
beads. Optimization of the amount of protein used for screening was carried out using a 
352 compounds library, with 100, 50, 25, 12.5, 6.25 and 3.125 µg of Pepsin in 100 µL of 
resin beads.  For the Carbonic Anhydrase experiments 120, 60, 30, and 6 µg of protein 
was coupled to 100 µL of resin beads.  
Library compounds were diluted from, 14.2 µM to 150 nM in incubation buffer prior 
to incubation with the immobilized protein. Then, 200 µL of the library mixture was added 
to 100 µL of immobilized protein mixture to make the final concentration of the library 
compounds 100 nM. Subsequently, the mixture was rocked for 1hr at room temperature. 
After incubation, tubes were centrifuged at 3000 × g for 5 minutes; the supernatant was 
removed and directly used in the LC-MS analysis.  All experiments using agarose were 
repeated and at least 3 times.  No changes were detected in the percent of compounds 
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that ionized in the control experiments (described later) or the identified inhibitors from 
the binding experiments (described above). 
2.2.3 Alternative binding procedure using magnetic beads. 
 
 Maltose binding protein (MBP) was immobilized on N-hydroxysuccinimide (NHS)-
activated magnetic beads by following the manufacturer’s protocol (PierceTM NHS-
Activated Magnetic Beads, Thermo Scientific). Briefly, after washing the magnetic beads 
per the manufacturer’s instructions, 100 µg of maltose binding protein in coupling buffer 
(PBS, 0.1 M; pH 7.4) was added to 300 µL of magnetic beads and slowly rocked overnight 
at room temperature. The supernatant was removed and the immobilized protein was 
washed with 1 mL of coupling buffer. After that, 300 µL of quenching buffer (Tris.HCl, 1.0 
M, pH 7.4) was added and slowly rocked for 2 hours. The supernatant was removed and 
the immobilized protein was washed with 2 mL of ammonium acetate (0.02 M, pH 8.0) 
incubation buffer. The supernatant was removed again and 50 µL of 352 compounds 
library mixture and a known inhibitor of maltose binding protein, maltotriose, was added. 
The final concentration of the library compounds was 100 nM. The mixture was then 
rocked for 1 hour at room temperature. After incubation, the supernatant was removed 
and directly used in the LC-MS analysis.  It was assayed three times to assure that the 
results were reproducible.  No changes were detected in the percent of compounds that 
ionized in the control experiment (described next) or the inhibitors identified in the binding 




2.2.4 Control Experiments 
 
 Coupling resin (agarose or magnetic beads) without protein, was used for the 
control experiments.  It was treated in the same way as described for its corresponding 
binding experiment, except no protein was added.  The same sets of library compounds, 
at the same concentrations as described above, were combined with the resin.  For each 
control experiment all conditions were identical to the matched binding experiment, and 
the LC-MS analysis, described below, was also conducted identically, for both the control 
experiments and the binding experiments.   
2.2.5 Capture and release experiment, an alternative testing method 
 
 The 352 compound library and a known strong inhibitor, ethoxzolamide, was 
incubated with 60 µg of immobilized Carbonic Anhydrase. The concentrations of the 
library compounds and the incubation conditions were replicated from the binding 
experiment.  After incubation, the supernatant was removed, and the immobilized protein 
was washed five times with incubation buffer. In each washing step, 1 mL of incubation 
buffer was added and vortexed for 10 s, followed by centrifugation at 3000 x g for five 
minutes. After washing was complete, 200 µL of acetonitrile was added to denature the 
protein, and the sample was kept at 70oC for 10 minutes. The sample was centrifuged at 
3000 x g for five minutes and the supernatant was analyzed using LC/MS.           
2.2.6 LC/MS Analysis 
 
  Liquid chromatography/mass spectrometry analysis was done using an Acquity 
UPLC system (Waters Corporation, Milford, MA) coupled to an Orbitrap Velos Pro mass 
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spectrometer. Mobile phase A was 99.9% water with 0.1% formic acid and mobile phase 
B was 99.9% MeOH with 0.1% formic acid. For each run, 5 µL of the supernatant was 
injected onto a C18 Hypersil Gold column (Particle Size: 5 µm; 1 mm i.d X 100 mm, 175 
Å, Thermo Electron Corporation, Thermo Fisher Scientific, Pittsburgh, PA) at a flow rate 
of 50 μL/min.  The following multi step gradient was used for the limited library:  The 
column was equilibrated at 98% solvent A for 5 min.  Solvent B was linearly increased to 
30% in 3 min, followed by a linear increase of solvent B to 60% in 10 min and a final linear 
increase to 98% in 2 min, where the solvent composition was maintained for an additional 
3 min.  The multi-step gradient used for the large libraries (176 compounds, and 352 
compounds) was as follows: 100% solvent A for 5 min, then a linear increase of B to 10% 
in 5 min, followed by the linear increase of B to 60% in the next 30 min, followed by 
another linear increase to 85 % in additional 10 min, followed by a linear increase to 95 
% in the final 7 min, where the column was maintained for another 3 min. A short wash 
and a blank run were carried out to ensure there was no sample carryover between runs. 
The eluent was diverted to waste for 5 min at the beginning of each run except for the 
experiments conducted with maltose binding protein, where the time was reduced to 1 
min, to prevent salts and DMSO from entering the MS source. The mass spectrometer 
was operated in the positive ion mode with a 3 kV potential on the ESI needle, and the 
capillary temperature was set at 250 ºC. Full scan MS data were acquired at a mass range 
of m/z 150-1000 using the Orbitrap mass analyzer at a resolution of 30,000 for m/z 400.  
All LC-MS data were interrogated using the MS analysis software, Apex (Sierra 
Analytics, Modesto, CA), which identifies compounds based on both mass match and a 
match of the isotopic distribution. The molecular formulas were input, and the software 
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extracted chromatograms of each compound from the .raw data files.  All analyses were 
conducted using a 5 ppm mass accuracy threshold and an MS similarity score of 0.05. 
The spectral data of the compounds that were not identified by the software were 
manually identified. A mass accuracy of 5 ppm and the correct isotopic cluster pattern, 
especially the presence of C13 isotopic peak, were required for a positive identification 
during manual analysis. Blank runs for both the binding and control experiments were 
analyzed, in order to eliminate any false identification of compounds that could arise due 
to background contaminants.   
2.3 Results and Discussion 
 
Figure 1 shows a workflow of the screening method described in this manuscript.  
Coupling resin is used for both the binding assay and the control experiment.  In the 
binding assay, the protein is immobilized on the resin. The resin, without protein, is used 
for the control experiment.  After immobilization, the remaining active sites on the resin, 
for both the binding and control experiments, are blocked using Tris. The resins (agarose, 
or magnetic beads) are then incubated with the library compounds, and the unbound 
compounds are detected by analyzing the supernatants using LC-MS. The compounds 
that are absent in the spectrum acquired from the binding experiment compared to that 
of the control, are considered bound to the protein.  It should be noted here that the control 
experiment is used to determine which compounds are detectable in the assay.  Any 
compound not detectable in the control experiment could be assayed by a different 
ionization method, such as APCI.  However, these compounds are not false positives or 




Figure 1: Workflow used herein. The inhibitors/binders were incubated with the protein 
(and, separately, with blocked beads), removed, and analyzed by LC-MS.  Strong binders 
were identified by comparing the spectral data of the control and binding experiments. 
The binders are present in the data for the control experiment but absent in the data for 




The effectiveness of the approach was demonstrated in several experiments. First, 
the feasibility of the method was assessed using immobilized Pepsin and a limited (seven 
compound) protease inhibitor library, so the results could be compared directly to a 
previous method upon which this one was loosely based.15 Next, larger libraries of drug-
like candidates were incubated with the protein target, to demonstrate that the method 
was amenable to larger sets of compounds.  Subsequently, the amount of protein was 
reduced, to demonstrate the method was scalable to very large screens where thousands 
of compounds could be tested.  We demonstrated that the assay could be tuned to only 
identify inhibitors with the strongest binding constants by optimizing the amount of protein 
used.  Finally, we demonstrated that the assay was transferrable to other protein/inhibitor 
analyses and to detecting inhibitors with Ki’s approaching the micromolar range. 
2.3.1 Feasibility study 
 
A well-studied, limited protease inhibitor library15 was used for proof of concept.  
Pepsin, immobilized on agarose, was incubated with a small number of protease 
inhibitors, including one strong Pepsin inhibitor, pepstatin A, and the raw data from this 
experiment is shown in Figure 2.  Overlaid selected ion chromatograms (SICs) of the 
seven compound inhibitory library incubated with blocked resin beads (from the control 
experiment) and after incubation with immobilized Pepsin (from the binding experiment) 




Figure 2: Selected ion chromatograms of known protease inhibitors, from the (a) control 
and (b) binding experiments. Pepstatin A  (blue trace) was not detected in the binding 
experiment (b) because it is a strong binder compared to other compounds. Seven known 
protease inhibitors were used in both experiments.  They are (in order of increasing 
retention time): antipain, black; leupeptin (red); bestatin (green); (+)-diisopropyl L tartarate 




Analysis of data from both the control experiment (Figure 2a) and binding 
experiment (Figure 2b) shows only one compound, pepstatin A is absent in the binding 
experiment, indicating it is the single strong-binding inhibitor. This result is significant 
because pepstatin A is the strongest binder to Pepsin in the group of compounds.  In 
earlier work by Cancilla et. al,15 several compounds were identified as potential inhibitors, 
including pepstatin A.  In the previous experiment, any compound whose MS signal was 
reduced, compared to the signal obtained prior to incubation with the protein, was 
identified as a potential inhibitor.  Therefore, weak and/or nonspecific binders were 
detected as possible hits.   In contrast to the protocol by Cancilla et al, the strongest 
binders can be exclusively identified if the detection strategy requires that the binder be 
completely absent after incubation with the protein. This change in detection strategy was 
intended to eliminate false positives and weak binders that are commonly detected in MS-
based screening assays.  The method was further adapted for high throughput screens 
by reducing the protein requirements and increasing the number of compounds to be 
analyzed in one batch, as described next.  
2.3.2 Testing large libraries  
 
The number of compounds that were incubated with immobilized Pepsin was 
increased ~20 fold in order to investigate the method’s capacity for screening large 
numbers of compounds.  Figure 3 illustrates the results from screening 176 compounds 
in one analysis while simultaneously scaling back the protein consumption by more than 
a factor of 20, from 10 mg to 450 µg.  Figure 3a shows a representative TIC from this 
experiment, demonstrating that the library compounds elute throughout the course of the 
experiment.  Each compound in the library was searched for individually in the dataset 
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using Apex, as described in the experimental section.  Comparison of data from the 
control experiment and binding experiment shows only one compound, the known 
inhibitor, is present in the control and absent in the binding experiment. Data in Figures 
3b and 3c show the selected ion chromatograms for pepstatin A, demonstrating that it is 
identifiable as a Pepsin binder.  These data clearly demonstrate the method’s potential 
for high specificity, high throughput screens.  
 
Figure 3: (a) Selected Ion Chromatogram (SIC) of pepstatin A in (a) overlaid on TIC. (b) 
SIC of pepstatin A in the control experiment, and (c) in the presence of 450 µg of pepsin 
in the binding experiment. pepstatin A was not detected in the binding experiment 
because it is a strong binder. A large library of 176 compounds and the known inhibitor 





In an effort to further test the method, the number of library compounds was 
doubled again (from 176 to 352), and the amount of Pepsin used for binding experiment 
was further reduced from 450 µg to 100 µg.  Again, only the known inhibitor is absent in 
comparing the data from the control experiment and the binding experiment; see Figure 
4.  The number of detectable compounds in the control experiment was 313, or ~88% of 
the total number of compounds assayed.  The compounds that were not detectable in the 
control experiment (~12%) would need to be assayed by another method.  They are not 
false positives or false negatives. Overall, the results from the 176 compound library and 
the 352 compound library demonstrate that large numbers of compounds can be 
analyzed in batches and that the protein necessary for these types of experiments is 




Figure 4: Selected Ion Chromatogram of Pepstatin A in (A) Control experiment overlaid 
on TIC, (B) in the control experiment, and in the presence of (C) 100 μg of pepsin in the 
binding experiment. 352 library compounds and known inhibitor (each with 100 nM 
concentration) were used in all experiments. 
2.3.3 Optimization of the protein amount  
 
One important measure of a good of high throughput screening method is the 
ability to test large numbers of compounds on small quantities of protein.  Therefore, we 
asked the question:  What is the minimum quantity of protein needed to detect pepstatin 
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A, while still screening >350 compounds at a time?  Figure 5 illustrates the MS data 
collected in a number of experiments where the amount of Pepsin was systematically 
reduced in order to determine the minimum amount of the protein needed for assay to 
remain successful.  (A successful assay is one in which the known, strong inhibitor, 
peptstatin A, does not appear in the selected ion chromatogram when analyzing the 
supernatant from the binding experiment.)  Several quantities of Pepsin were tested, 
including 50 µg, 25 µg, 12.5 µg and 6.25 µg.  In each case, the pepstatin A was not 
detected in the supernatant from the binding experiments. However, when the amount of 
Pepsin was reduced to 3.125 µg, the inhibitor finally appeared in the chromatogram 
(Figure 4b). These data demonstrate that the high throughput screening campaign could 
be conducted on a scale that consumed as low as 6 µg (171 pmol) of protein to screen 
batches of >350 compounds.  We expect that this protein quantity is at the low end of 
what one would want to use in this kind of assay, particularly if weaker-binding ligands 
are targeted. This inhibitor has a very low Ki, 45 pM, so it is likely to be a very strongly 
binding inhibitor. Additional experiments, below, indicate that the assay can be done on 
less than 100 µg of protein per well, even when lower-affinity binders are to be detected.   
In each of the experiments described above, all the other compounds that are observed 
in the control experiment, except the inhibitor, were also observed in the binding 
experiments, demonstrating that zero false positives were identified, which is a key 




Figure 5: Selected Ion Chromatogram of pepstatin A in (a) Control experiment overlaid 
on TIC, and in the presence of (b) 0 µg (Control), 50 µg, 25 µg, 12.5 µg, 6 µg, and 3 µg 
of Pepsin in binding experiments. A library of 352 compounds and the known inhibitor 
(each with 100 nM concentration) were used in all experiments.  
 
2.3.4 Application to a new protein, Carbonic Anhydrase (CA) 
A second protein target, Carbonic Anhydrase (CA) immobilized on agarose beads, 
along with the 352 compound library described above, was used to further demonstrate 
the feasibility of this screening method. The library was spiked with two known CA inhibitor 
standards; ethoxzolamide with Ki of 700 pM ,and sulpiride with Ki of 63 µM.  The data in 
Figure 5a show the TIC for the control experiment, and Figure 5b contains the data from 
the binding experiment.  In each case, the SICs of two known inhibitors, ethoxzolamide 
(red) and sulpiride (blue) are overlaid in the Figures. Inserts show the mass spectral data 
for each inhibitor.  Approximately 88% (312) of the compounds were detected from the 
352 compounds in the control experiment (Figure 6a). All 312 compounds that were 
observed in the control experiment were also observed in the binding experiment, except 
ethoxzolamide, the strong inhibitor (Figure 6b). Even though sulpiride is known to be a 
CA inhibitor, it was not identified as such in this experiment since the Ki is rather high (63 
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µM). These data demonstrate that only the strongest binders are identified using this 
approach.   
 
Figure 6: TIC of the (a) control and (b) binding experiments (with 120 µg of CA), including 
selected ion chromatograms of two known CA inhibitors, ethoxzolamide (red), and 
sulpiride (blue), overlaid. Ethoxzolamide was not detected in the binding experiment 
because it is a strong binder. Every other compound detected in the control experiment 
(a) was also detected in the binding experiment (b), including the weak binder.  This 
experiment shows that zero false positives were detected and that the assay is selective 




We optimized the assay to determine the minimum amount of protein required to 
detect ethoxzolamide. These data are presented in Figure 7.  When 60 µg of CA was 
used, ethoxzolamide was not detected. When the amount of CA is reduced in half, 
significant spectral data were observed for the inhibitor, and even more intense spectral 
data were observed with the use of 6 µg of CA. These results indicate that approximately 
60 µg of the protein is needed to identify this inhibitor, which has a Ki of 700 pM.  We 
demonstrated in Figure 5 that the amount of protein required for this assay is substantially 
less, if stronger binding inhibitors are to be identified.  Specifically, just 6 µg of protein 
was necessary to test 352 compounds and selectively identify an inhibitor with a Ki of 45 
pM.  In comparing the data herein for Carbonic Anhydrase (6 pmol protein per compound 
was required to identify a compound with a Ki of 700 pM) and the previous assay (0.5 
pmol of protein per compound was required to identify a compound with a K i of 45 pM), 
one can see that the amount of protein required for the assay is roughly proportional to 
the Ki for the compound to be detected.  The strongest binding inhibitors can be detected 





Figure 7: (A) SIC of Ethoxzolamide in (A) the control experiment overlaid on TIC and in 
the presence of (B) 0 µg (Control), 120 µg, 60 µg, 30 µg, and 6 µg of CA in binding 
experiments. 352 library compounds and two known CA inhibitors (each with 100 nM 
concentration) were used in all experiments. 
2.3.5 Detecting lower affinity ligands. 
 
 To screen for the inhibitors in Ki ~ µM range using the immobilization conditions 
described above, a large amount of protein would be required.  To successfully conduct 
the HAMS assay with lower affinity ligands, the protein can be immobilized on magnetic 
beads instead of agarose.  This change in immobilization conditions is necessary 
because the beads can then be removed from the supernatant without centrifugation, so 
weak protein-ligand complexes are not disturbed while separating the proteins from the 
ligands  
To demonstrate that the HAMS method can identify inhibitors with Ki’s approaching 
the µM range, a screening was conducted using Maltose Binding Protein (MBP), 
immobilized on magnetic beads, and a 352 compound library, which was spiked with a 
known MBP inhibitor, maltotriose, with a Ki of ~ 0.2 µM. The data in Figure 8a show the 
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SIC of maltotriose in the control experiment, where the peak is clearly detectable.  The 
maltotriose peak completely disappears in the binding experiment, as shown in Figure 
8b. The data clearly illustrate that maltotriose binds to the protein and can readily be 
detected as a hit in the HAMS assay.  Similar to the previous assays, not one false 
positive hit was detected.  Every compound that appeared in the control experiment was 
also detected in the binding experiment, except the known inhibitor.  These data show 
that it is fully feasible to screen for inhibitors with Ki approaching = 0.2 µM using the HAMS 
assay. In this case, less than 7 pmol of protein was needed per compound screened.      
 
Figure 8: Selected ion chromatograms of known maltose binding protein (MBP) inhibitor: 
maltotriose, in (A) control and in the presence of (B) 100 µg of MBP in the binding 
experiments. 352 library compounds and known inhibitor (each with 100 nM 




2.3.6 Comparison to alternative testing methods. 
One major benefit of the described method is its consistent ability to identify only 
the strongest inhibitors, substantially eliminating false positive interactions.  Other MS-
based screening methods have not yet been capable of identifying only the strongest 
inhibitor present.  With this in mind, we asked the question:  Did we just get lucky and test 
a bunch of compounds that would not show up as false positives in other assays either?  
To answer the question, the library of 352 compounds was used to determine how many 
false positives would have been identified as Carbonic Anhydrase binders in the ASMS 
method, a state-of-the-art screening approach.   
To screen the compounds using the ASMS method, the 352 potential binders 
(used in Figure 5) were incubated with CA; the non-binders were removed, and the protein 
was washed using stringent conditions, as described in the experimental section.  The 
protein was deactivated, and released compounds were analyzed using LC-MS, following 
the procedure described in reference 9.  Using this approach, one could still detect the 
presence of the strong inhibitor.  However, in addition to this compound, 30 other non-
inhibiting compounds were also detected.  (See Table 1.)  This experiment emphasizes 
the advantage of the newly described protocol over existing methods.  Even though the 
protein was washed thoroughly prior to releasing the bound compounds, almost 10% of 
the ligands were detected as potential binders.  Thus, the traditional high throughput 
screening approach may leave the investigators with numerous compounds for further 
investigation, when in fact, only one of them would be desirable to detect in this case, the 
known inhibitor with Ki in the pM range.   
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Table 1: The list of compounds that were detected as false positives in the capture and 





Even though the ASMS method suffers from a large number of false positives, it is 
perhaps best described as complementary to the HAMS method, instead of inferior to it, 
when all metrics are considered.  The ASMS method’s two key advantages are its rapid 
throughput and simple data analysis.  The throughput of the HAMS method is about 5,000 
compounds per day, whereas the ASMS method can process more than twice as many 
compounds in the same timeframe.  Additionally, the ASMS method, which relies on 
detecting inhibitors based on the presence of their MS signal, has a simpler data analysis 
workflow compared to HAMS, which relies on disappearance of the analyte’s 
signal.  Therefore, these two methods are quite complementary.  A method that could 
deliver the speed and simplicity of ASMS, along with the complete absence of false 
positives, like HAMS, would be a remarkable advancement in the field. 
2.3.7 Investigation of the undetected compounds 
 
 In all the large screening assays we conducted, ~88% of compounds were 
observed for both the control and binding experiments.  In other words, ~12% of the 
compounds were not detected in the control experiment and therefore, not assayable.  
They were not false positives or false negatives.  They were simply not testable 
compounds.  If these compounds were not detectable due to the assay conditions or due 
to matrix effects, that would represent a potential weakness that would need to be 
considered prior to selecting this assay for a large screen.  Therefore, we examined the 
reasons behind their absence in the data sets.  
The undetectable compounds from the Carbonic Anhydrase screen were tested 
individually, to determine if they were undetected due to poor ionization efficiency, or due 
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to the assay, or due to matrix effects.  Each compound was prepared individually and 
subjected to direct infusion experiments, but none of the compounds were detected in the 
positive ion mode during these experiments, indicating that all the compounds that 
possibly can be observed using positive mode ESI were successfully detected in the 
Carbonic Anhydrase screen.  The undetected compounds also were individually tested in 
negative ion mode, and only 17 were detected.  These compounds could potentially be 
detected if the LC-MS analyses were to be repeated in negative ion mode; however the 
value of that experiment would have to be balanced against the analysis time required to 
perform it.  In sum, 7% of the compounds did not ionize at all by ESI.  Those compounds 
were, therefore, not detected in the screen.  Of the remaining 93% that were ionizable by 
ESI, 312 out of 329 were detected in one chromatographic run, using only positive ion 
mode, with no gradient optimization performed.  Overall, these experiments demonstrate 
that the number of detectable compounds is not limited by the assay conditions or matrix 
effects; rather, it is directly related to the ability of the compounds to ionize by ESI-MS.   
Every MS-based assay suffers from the fact that it cannot detect compounds that don’t 
ionize.  The HAMS assay is unique in that it can identify these compounds as “untestable”, 
and they are not mistakenly characterized as false positives or false negatives. 
2.4 Conclusion  
 
 Inhibitors were quickly identified for three different proteins by comparing the mass 
spectra of the library molecules before and after incubation with immobilized protein. In 
every experiment conducted, all the compounds that were observed in the control 
experiment were also observed in the binding experiments, except the known inhibitors. 
This observation indicates that the method described herein is unprecedented for MS-
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based assays in that the false positive detection rates are exceedingly low, approaching 
zero.  This method was used to selectively detect inhibitors that have Ki values of 50 pM 
(with Pepsin), 700 pM (with Carbonic Anhydrase), and the minimum amount of protein 
needed for these assays was 0.5  and 6  pmol per compound, respectively, was used for 
screening. These results indicate that one can control the affinity of the ligands detected 
by controlling the amount of protein used in the assay, a feature which has not been 
demonstrated by other MS-based screening assays.  By using magnetic beads for protein 
immobilization, inhibitors with Ki’s in the micromolar range could also be assayed, using 
just 7 pmol of protein per compound screened.  Finally, the method compares very 
favorably to the state-of-the-art MS-based assay (ASMS),9 where the false-positive 
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Chapter 3: A Rapid LC-MS Based High-Throughput Screening Method That   
Affords No False Positives or False Negatives and Identifies a New 
Nanomolar Affinity Inhibitor for the Therapeutically Valuable Protein, 
Carbonic Anhydrase 
 
Developing effective high-throughput screening (HTS) methods is of paramount 
importance in the early stage of drug discovery. While rugged and robust assays may be 
easily developed for certain enzymes, HTS assays designed to identify ligands that block 
a protein binding site are much more challenging to develop.  In these protein binding 
assays, ruling out false positives and false negatives under high-throughput conditions is 
particularly challenging.  To overcome these challenges, we developed an MS-based 
HTS assay that has several major advantages over existing methods. The assay 
mitigates false positives by selectively identifying positive hits exclusively when a ligand 
at the binding site of interest is displaced; it mitigates false negatives by detecting a 
reporter compound that ionizes well, not by detecting the ligand binder, which may not 
ionize.  This interrogation approach allows non-ionizable compounds to be assayed.  The 
screening is fast (400 compounds in 10 minutes) and requires low (nanogram) amounts 
of target protein per compound. It can detect binders with Kd’s in the picomolar to 
micromolar range. The method was validated by detecting known binders of three 
proteins, pepsin, Maltose Binding Protein (MBP), and Carbodic Anhydrase (CA) in the 
presence of hundreds of non-binders.  We also identified a novel CA binder, pifithrin-µ, 
which could not have been identified by any other MS-based assay because of its poor 
ionization efficiency.  This new method addresses many of the challenges that are 





Identifying potent and high affinity ligands for target proteins is a vital first step in 
drug development.  Generally, these molecules are identified during high-throughput 
screening campaigns, and the most commonly used analysis methods are florescence,1,2 
chemiluminescence,3 and surface plasmon resonance (SPR).4 All of these methods 
suffer from the same limitation:  modification of the analytes or the protein is typically 
necessary for detection.   Thus, assay development can be laborious, and the molecular 
labels themselves can alter the integrity of the binding between ligands and the target 
protein, leading to false positives and false negatives. Although nuclear magnetic 
resonance (NMR) is an alternative label free spectroscopy technique,5,6  it requires 
substantially more protein, and data analysis is laborious, resulting in very low throughput. 
As a result of the continued need for fast, label-free detection methods, mass 
spectrometry (MS) based screening techniques are becoming more common.  The key 
advantages of an MS-based method are the label free nature, high sensitivity, and the 
ability to differentiate ligands based on the analytes’ masses.    
Various MS-based techniques have been developed over the past few decades, 
and these methods can be subdivided into those approaches that either do or do not 
require a chromatographic separation step as part of the analysis. The most commonly 
used MS-based methods without chromatography rely on MALDI-TOF-MS.7,8,9 This MS 
platform is fast and sensitive, but matrix interferences and poor reproducibility are some 
shortcomings that can contribute to false positive and false negative identifications.10,11 
Common MS-based HTS methods that incorporate a separation step allow for more 
compounds to be interrogated at one time; example separation platforms include size-
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exclusion chromatography coupled with reverse phase chromatography-MS (SEC-RPC-
MS),12 ultrafiltration-MS,13 gel filtration-MS,14 frontal affinity chromatography-MS,15,16 and 
affinity capillary electrophoresis-MS.17  In these methods, binders are generally identified 
either by direct detection of the protein-ligand complex,12 or by detection of bound 
compounds after dissociation of the protein-ligand complex,14-16,18 or by detection of 
unbound compounds compared with a control.18  The most common limitations to these 
approaches are false positives, due to non-specific binding, false negatives, due to the 
presence of non-ionizable compounds, the need for large amounts of target protein, and 
insufficient throughput.12,14,19,20   
The most commonly used MS-based HTS method is the affinity selection–MS 
screening method (ASMS).  This approach currently has the best balance of strengths 
and limitations, and it can be used for screening over 1×105 compounds per day.21,22,23,24 
While this level of throughput is a clear advantage, false positives, which are due to 
nonspecific binding of small molecules, introduce a significant disadvantage.12,14,19 As 
such, the hits from this type of screen need to be validated with an alternative screening 
technique in order to completely rule out possible false positives. Additionally, the method 
is not able to detect hits that do not ionize, so false negatives are also a concern.   
Recently, we reported a novel MS-based HTS method, High-Affinity Mass 
Spectrometry screening (HAMS), which uniquely evades the detection of false positive 
hits.25 However, the method requires acquisition of two LC-MS datasets per set of 350 
compounds, and this requirement limits throughput. Therefore, further development in 




Herein, a new approach is developed that fills the existing technology gaps in high-
throughput screening.  This method avoids false positives and false negatives; it can be 
used to screen over 10,000 compounds per day, while consuming limited protein 
quantities.  Target proteins are incubated with a known ionizable weak binder (reporter 
molecule), and the complex is then introduced to a batch of library compounds, while an 
equimolar amount of the complex, without the library compounds, is used as a control 
sample. LC-MS is used to detect the reporter molecule. If a stronger binder is present in 
the library, the signal of the reporter molecule increases compared to the molecule’s 
signal in the control samples. In this way, a binding event is measurable, even if the 
strong-binding ligand is not detectable by mass spectrometry; in other MS-based assays, 
non-ionizing compounds result in false negatives.  In addition, the assay has very modest 
protein requirements, consuming ng of protein per compound analyzed. . Finally, the 
analysis time for the method described herein is a quick 10 minutes per batch of 300-400 
compounds, which extrapolates to well over 10,000 compounds per day. Overall, this MS-
based HTS method meets the current needs of the drug discovery field better than any 
existing MS-based method.  Furthermore, the assay’s value is demonstrated by 
identifying a new inhibitor for Carbonic Anhydrase, a therapeutically valuable protein. 




FDA approved drug compounds (1280 compounds) were purchased from Sigma 
Aldrich (St. Louis, MO). The library was provided as a single compound per vial 
(LOPAC1280-small scale), dissolved in DMSO at a concentration of 10 mM. Pepsin, 
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Aminolink Plus coupling resin, and disposable plastic columns were obtained from Pierce 
Biotechnology, Inc. (Rockford, IL). PierceTM NHS-Activated Magnetic Beads were 
purchased from Thermo Scientific (Workford, IL). Maltose Binding Protein and Carbonic 
Anhydrase were purchased from My BioSource (San Diego, CA) and Sigma Aldrich 
(Milwaukee, WI), respectively. Nitrocellulose drop dialysis membranes were purchased 
from Fisher Scientific (Houston, TX).  
3.2.2 Protein immobilization onto Aminolink Plus coupling resin 
 
Immobilizations of Carbonic Anhydrase (CA) and  pepsin  were carried out by 
adjusting a previously published procedure.56 Each protein was maintained at its optimal 
pH.  Therefore, for CA the coupling buffer was phosphate buffered saline (PBS) (0.1 M, 
pH 7.4), the blocking buffer was Tris HCl (1.0 M, pH 7.4), the incubation buffer was 
ammonium acetate (0.02 M, pH 7.4), and the wash buffer was 1 M NaCl in coupling buffer. 
Similarly, for pepsin, citric acid and NaHPO4 (0.1 M, pH 4.5) were used as the coupling 
buffer; the blocking buffer was Tris HCl (1.0 M, pH 4.5), the incubation buffer was 
ammonium acetate (0.02 M, pH 4.0), and the wash buffer was 1 M NaCl in coupling buffer. 
All of the pepsin assays were carried out through immobilization of 1 or 2 µg of pepsin 
with 25 µL of resin beads. Similarly, 10 µg of carbonic anhydrase was coupled to 25 µL 
of resin beads. 
Both CA and pepsin were dissolved in 100 µL of coupling buffer before drop 
dialysis was conducted. Dialysis of the dissolved proteins with the coupling buffer was 
performed over 1 h using a 0.025 mm nitrocellulose drop dialysis membrane.  
Subsequently, the protein was added to a disposable plastic column that was filled with 
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coupling resin which had been washed with 2 mL of coupling buffer. Then, a solution of 
1 M NaCNBH4, in coupling buffer, was added to the resin solution until a final 
concentration of 50 mM NaCNBH4 was reached. The column and resin solution was 
rocked overnight, then washed with 10 mL of coupling buffer, followed by 5 mL of blocking 
buffer.  Next, 1mL of blocking buffer was added, and 1M NaCNBH4 was added again until 
a final concentration of 50 mM NaCNBH4 was reached. The mixture was rocked for 2 h, 
and the column was washed with 10 mL of coupling buffer, 10 mL of wash buffer, and 15 
mL of incubation buffer, in that order. Finally, the immobilized protein was transferred to 
Eppendorf tubes for incubation with the library compounds immediately.  
3.2.3 Preparation of library compounds for binding experiment 
 
To prepare the 100-compound libraries, 2 µL of each compound’s stock solution 
(10 mM) was combined into 100 compound batches at a final concentration of 100 µM. 
Then, 2 µL of the 100 µM batches (100 compounds each) was diluted with incubation 
buffer, specific to each protein, to obtain a 25 µM stock solution. When preparing the 
library of 400 compounds, 2 µL solutions from each of the four libraries of 100 compounds 
were combined, achieving a final concentration of 25 µM. Then, for both libraries of 100 
or 400 compounds, 2 µL of the 25 µM library was diluted to 337.5 nM using the incubation 
buffer, specific to each protein.  
3.2.4 Binding experiment using proteins immobilized on Aminolink coupling resin. 
 
Immobilized pepsin and CA were incubated with 200 μL of 300 nM known weak 
binders, pepsinothipsongen or methoxzolamide respectively. After incubation, tubes were 
centrifuged at 3000 × g for 5 minutes; the supernatant was removed, and the immobilized 
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proteins were washed twice with 500 μL of incubation buffer. Next, 200 µL of the 100 or 
400 compound library mixture was added to 25 µL of immobilized protein mixture, bringing 
the final concentration of the library compounds down to 300 nM. The mixture was rocked 
for 1 h at room temperature, then centrifuged at 3000 × g for 5 minutes; the supernatant 
was removed and used directly for LC-MS analysis. 
3.2.5 Binding experiment for low-affinity binders. 
 
Maltose binding protein (MBP) was immobilized on N-hydroxysuccinimide (NHS)-
activated magnetic beads by following the manufacturer’s protocol. Briefly, drop dialysis 
was conducted on MBP in PBS buffer (0.1 M, pH 7.4). Then, 100 µL of magnetic beads 
were washed according to the manufacturer’s instructions and 20 µg of MBP in coupling 
buffer (PBS, 0.1 M, pH 7.4) was added. The mixture was slowly rocked overnight at room 
temperature. Subsequently, the supernatant was removed, and the immobilized proteins 
were washed with 1 mL of coupling buffer. Then, 300 µL of quenching buffer (Tris HCl, 
1.0 M, pH 7.4) was added and the mixture was rocked for 2 hours. The supernatant was 
removed, and immobilized proteins were washed with 300 µL of washing buffer (1 M NaCl 
in coupling buffer) followed by 2 mL of ammonium acetate (0.02 M, pH 8.0) incubation 
buffer. The supernatant was removed again and 50 µL of 50 nM maltose, a known weak 
binder, was added. The mixture was rocked for an additional two hours at room 
temperature. After removing the supernatant, 50 µL of the 400 compound library (300 
nM) was added, and the mixture was rocked again for one hour. After incubation, the 




3.2.6 Positive and Negative Controls 
 
Positive and negative control samples were prepared, as explained in the binding 
experiments section above, for high and low affinity ligands, except libraries with a known 
strong binder were used as positive control samples. For each positive control, 401 library 
compounds were used. Negative control samples contained either buffer only or 400 non-
binding compounds.  Supernatants for both controls were removed and subjected to LC-
MS analysis. 
3.2.7 LC/MS Analysis 
 
An Acquity UPLC system (Waters Corporation, Milford, MA) coupled to an Orbitrap 
Velos Pro Mass Spectrometer was used for liquid chromatography/mass spectrometry 
analysis. Mobile phase A was 99.9% water with 0.1% formic acid, and Mobile Phase B 
was 99.9% MeOH with 0.1% formic acid. Five microliters of the supernatant was injected 
onto a C18 Hypersil Gold column (Particle Size: 5 µm; 1 mm i.d X 100 mm, 175 Å, Thermo 
Electron Corporation, Thermo Fisher Scientific, Pittsburgh, PA) at a flow rate of 50 μL/min. 
The multi-step gradient used for assays, excluding any analyses for MBP, was as follows: 
100% solvent A for 1 min, then a linear increase of B to 80% in 4 min, followed by the 
linear increase of B to 95% in the next 3 min; then  B was maintained at 95% for an 
additional 30 seconds, finally a linear decrease of B to 0% in the next 30 seconds, where 
the solvent composition was maintained for another 2 min. The following multi-step 
gradient was used for MBP assays: 100% solvent A for 3 min, then a linear increase of B 
to 80% in 2 min, followed by the linear increase of B to 95% in the next 3 min, then B was 
maintained at 95% for an additional 30 seconds, finally, a linear decrease of B to 0 % in 
75 
 
next 30 seconds, where the column was maintained for another 2 min. The eluent was 
diverted to waste for 7 minutes at the beginning of each run, except for the experiments 
conducted with MBP, where the divert time was reduced to 1 min. The mass spectrometer 
was operated in the positive ion mode with a 3 kV potential on the ESI needle, and the 
capillary temperature was set at 250 ºC. Full scan MS data were obtained at a mass range 
of m/z 200-700 using the Orbitrap mass analyzer at a resolution of 30,000 for m/z 400.   
All peak areas were calculated using the extracted ion chromatograms from the 
.raw data files for each compound. The extracted ion chromatograms were generated for 
the monoisotopic peaks of protonated or/and sodiated adducts for every reporter 
molecule as follows: pepsinostreptin (m/z 672.4548), methoxzolamide (m/z 237.0110), 
maltose (m/z 343.1235, 365.1054), and chlorothiazide (m/z 295.9561). The peak area for 
each extracted ion chromatogram was calculated using the software (Xcaliber) supported 
algorithm, Genesis. 
3.2.8 Calculation of IC50 of pifithrin-µ 
 
IC50 was determined by plotting the % inhibition versus the log of the 
concentration of the inhibitor, adapting a well-established method.26 Experiments were 
repeated in triplicate. For each trial, 100 µL of 0.125 mg/mL carbonic anhydrase (4.3 µM) 
in Tris buffer (pH 8.4) was used. First, the protein solution was mixed with 9.9 mL Tris 
buffer containing different concentrations of inhibitor. The inhibitor concentrations were 0 
nM, 1 nM, 5 nM, 10 nM, 20 nM, 40 nM, 60 nM, 100 nM, 130 nM, 200 nM, 350 nM, 500 
nM, 1 µM, 2 µM, 4 µM, 6 µM, 8 µM, and 10 µM.  These protein-inhibitor mixtures were 
incubated for 1 hour on a rocking platform at 4o C (on ice). After incubation, 4 mL of 
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carbonated Tris buffer, which was pre-equilibrated at 4o C (on ice), was added with 
stirring. The final concentration of the protein in the reaction mixture was 0.03 µM. 
Simultaneously, the pH of the solution was recorded over time. The time required for the 
pH of the solution to change from 8.4 to 6.4 was recorded in order to calculate the % 
inhibition. The entire reaction was carried out at 4oC (on ice) with stirring. The % inhibition 
was calculated using the following equation: % inhibition = [(normal activity – inhibited 
















3.3 Result and discussion: 
 
3.3.1 Method Overview 
 
Figure 1 describes the workflow for the assay developed herein.  Immobilized 
protein of interest is first incubated with a compound known to bind to the target protein; 
hereafter, this compound is referred to as “the weaker binder” or “reporter molecule”, 
although its binding affinity can be in the micromolar to picomolar range. After incubation, 
excess weaker binder is removed with the incubation buffer, and the immobilized protein 
/ weaker binder complex is incubated with the library compounds of interest; typically 
batches of 400 compounds are tested. If the library contains a stronger binder, the high 
affinity binder competes for the same binding site in the protein with the known weaker 
binder. The weaker binder is, therefore, displaced from the complex. Hence, the impact 
of a stronger binding compound being present is that the concentration of the weaker 
binder in the supernatant increases compared to that of the negative control, when no 
library compounds are added. Although no strong binders are present in the negative 
control, a certain degree of dissociation of the weaker binder from the protein occurs, 
depending on the concentrations of the protein and ligand and the strength of the binding 




Figure 1: Experimental workflow. The weaker binder (reporter molecule) is incubated 
with the immobilized protein, and the excess reporter molecule was washed off.  The 
library compounds are added to the test sample.  During validation experiments, a 
known strong binder is spiked into the library, generating a positive control sample.  
When present, a strong binder replaces the reporter molecule on the binding site of the 
protein, and the concentration of the reporter molecule increases in the supernatant 
relative to the negative control. Supernatants for both the negative control and the test 
samples are analyzed for the presence of reporter molecule, and the peak area of the 
reporter molecule is used to calculate the Z’ factor during validation experiments. 
To demonstrate that this workflow provides sufficient discriminatory power 
between ligand sets that do or do not have a strong binder present, several control 
experiments were completed on different protein/ligand systems.  During these control 
experiments, a stronger binder is always included in the positive control.  Three model 
proteins (pepsin, Carbonic Anhydrase (CA), and Maltose Binding Protein (MBP)), their 
known weaker binders, and their known strong binders were used in three separate proof-
of-concept experiments. In each case, the peak area of the weaker binder in the positive 
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control was compared to the signal for the weaker binder in the negative control.  These 
peak areas were used to calculate a Z’ factor, which is a statistical measure used to 
determine the quality of an HTS assay.27 If the Z’ factor is between 0.5 and 1.0, the assay 
is considered excellent, whereas if the calculated Z’ factor is <0.5 and > 0, the method is 
not considered to be very effective, by most standards.27 Each experiment is discussed 
in detail next, starting with the proteins that have known tight-binding inhibitors.   
3.3.2 Identification of high affinity binders (pM to nM range) 
 
The assay was first validated using proteins that have known high-affinity ligands.  
Immobilized pepsin and CA were incubated with their known binding ligands (reporter 
molecules), pepsinostreptin and methoxzolamide, respectively. For negative controls, the 
protein/ligand complexes were each incubated with a library of 400 compounds that did 
not contain any strong binders, while the validation samples (positive controls) were 
prepared by incubating the protein-reporter molecule complexes with the same library as 
the negative control and also the protein’s known stronger binder. One strong binder 
(pepstatin A, Kd = 50 pM) was used for pepsin, while two strong binders (Ethoxzolamide, 
Kd = 750 pM, and Brinzolamide Kd = 3 nM.), were used in two separate experiments for 
CA. After incubation with the library compounds, the negative controls and the positive 
controls were each centrifuged, and the supernatants were analyzed using LC-MS.  In 
each case, detection and quantification of the reporter molecule, the weaker binder, was 




Figure 2 shows the results of these experiments.   For both proteins, a significant 
increase of the reporter molecules was detected in the supernatant of the positive controls 
for all five trials compared to the five negative controls.  This result indicates that the 
strong binders in the positive controls displaced the weaker binders in the active sites of 
the proteins, leading to an increase of the weaker binders in the supernatant of the 
positive controls. The peak area of pepsin’s weaker binder is approximately four times 
larger in the positive controls than the negative controls (Figure 2a).   The peak areas for 
the weaker binder in both the positive and negative controls are reproducible; and the 
calculated Z’ factor is > 0.6, indicating that the assay is appropriate for high throughput 
screening of strong binders in the pM range. Figure 2b shows similar results for the two 
different CA binding experiments. The Z’ factors for both experiments are also greater 
than 0.6, falling into the “excellent” category for HTS assays of strong binders in the nM 
range. In addition, Figure 2b also shows slight differences in the peak areas of the reporter 
molecule for the two different strong binders for CA. The variation in peak areas in these 
two experiments is expected due to the difference between the dissociation constants Kds 
of the two binders.  These trials required only 1 µg (~30 pmol) of pepsin and 10 µg (~310 
pmol) of CA to screen 400 compounds in each library.  While the CA assay, which profiled 
a lower affinity ligand, required more protein, this protein quantity is still significantly lower 





Figure 2: Results of the validation experiments for (A) pepsin and (B) carbonic 
anhydrase.  The calculated Z’ factors indicate that the assays have appropriate 




3.3.3 Identification of transient binders (µM range) 
  
After successfully applying the assay to screen for tight-binding ligands, we tested 
whether the same procedure could be used to identify lower-affinity ligands.  In these 
experiments, maltose binding protein (MBP) was the target; maltose (Kd of ~3 µM) was 
used as the weaker binder (reporter molecule), while maltotriose (Kd =0.2 µM) was the 
stronger binder.  As before, the stronger binder was spiked into the positive controls, but 
not the negative controls.  No significant difference in the signal of the reporter ion in the 
positive and negative controls was detectable in these experiments.  In considering the 
potential reasons for the experiment’s failure, we suspected that the centrifugation step, 
which is necessary to separate the immobilized protein from the supernatant, was causing 
the weakly bound reporter molecule to dissociate from the complex to a significant 
degree, even when a stronger binder was not present.   
To address this problem, magnetic beads were used to immobilize the protein, 
instead of agarose beads.  Since magnetic beads were used, no centrifugation was done, 
thereby minimizing the dissociation of reporter molecules from immobilized protein due 
to the centrifugal force.  
 After making the aforementioned changes, MBP was immobilized on magnetic 
beads followed by incubation (loading) with the reporter molecule, maltose. 
Subsequently, the supernatant was removed without centrifugation and the MBP-maltose 
complex was incubated with library compounds. A library of 400 compounds was used 
for the negative control, for the positive control, maltoriose, the stronger binder, was 
spiked into the same library. Finally, the protein was sequestered from the supernatant 
without centrifugation, and the supernatant was then analyzed for the reporter molecule 
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using LC-MS. Five trials were conducted for each control. Figure 3 shows the results of 
the experiments. The increase in the amount of reporter molecules in the supernatant of 
the positive controls compared to negative controls indicates the experiment was a 
success. The calculated Z’ factor for the experiments was 0.53, showing that the assay 
can be applied for high-throughput screening of low-affinity binders.   
 
Figure 3: Results of the validation experiment for maltose binding protein.  The 
calculated Z’ factor indicates that the assay has appropriate discriminatory power for a 
high-throughput screen. 
Since our assay demonstrated the capability of use in HTS even for transient 
binders, we validated the assay by using a library of 1200 compounds (same library 
used in high affinity binders screening) to verify if the known spiked binder could be 
readily identified. Three sets of 400 compounds each were prepared, and one set was 
spiked with a known MBP binder, maltotriose (Kd = 0.2 µM). Library B (Figure 4) 
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contains the compound set with the known binder. The known strong binder was 
effective at out-competing the reporter molecule (maltose, Kd = 3 µM) that had initially 
been pre-loaded into the MBP binding site.  Figure 4B shows that in three replicate 
trials, the concentration of the reporter molecule was almost three times that of the 
concentration of the control sample, where no library compounds competed for binding.  
The reporter molecule was readily detectable in the supernatant, signaling that a 
compound in the library was out-competing it for MBP binding. Figure 4A and B also 
show results for the two other sets of 400 compounds, which have a value close to one. 
These values, shown in the Y axis, represent a ratio comparing the signal of the 
reporter ion in the presence and absence of the library compounds.    It is clear that only 
Library B had a strong binder, suggesting the capability of screening enhanced libraries 
for transient binders was feasible without any false identification. The amount of protein 
needed was ~ 20 μg to screen for Kd = µM binders in a 400-compound mixture.  The Kd 
was 1000 times larger for the transient binder compared to the Kd of the high affinity 
binders. However, we were able to develop this assay using only twice the amount of 




Figure 4: Peak area ratio of the weak binder, maltose, to the controls among all the 400 
compound libraries tested. The ratios for Library A and C are close to 1, indicating the 
absence of possible strong binders. Library B, where the strong binder, maltoriose, was 
spiked clearly showed a larger peak area. 
3.3.4 Addressing false negatives 
 
A significant limitation of current MS-based HTS methods is the high rate of false 
negative identifications due to non-ionizable compounds not being detected in MS-based 
assays. We carried out an experiment to demonstrate that the method described herein 
overcomes this limitation. The experiment was conducted using carbonic anhydrase (CA) 
as the model protein, chlorothiazide as the reporter molecule, and acetazolamide, which 
is a non-ionizable molecule, as the strong binder.  Figure 5 shows a pictoral description 
of the experiment along with the resulting data.  As shown in Figure 5A, acetazolimide is 
not detectable by ESI-MS when it is analyzed directly.  Figure 5B shows the signal for the 
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reporter molecule, chlorothiazide, when no strong binders are present in the assay; this 
is the negative control.  When acetazolamide is incubated with a CA-chlorothiazide 
complex, however, a significant increase of the peak area of the reporter molecule, 
chlorothiazide, is detectable.  This increase in signal can be seen by comparing the data 
in Figure 5B, the negative control, to the data in Figure 5C, when acetazolimide is present.  
The increase in concentration of the reporter molecule, chlorothiazide, in the supernatant 
is due to the competitive binding of the non-ionizable strong binder, acetazolamide, to 
carbonic anhydrase. Hence, the assay can identify the presence of strong binders from a 
pool of library compounds, irrespective of whether the compounds ionize well or not.  
 
Figure 5: (a) Selected ion chromatogram (SIC) of non-ionizing strong binder, 
acetazolamide.  (b) SIC of the weak-binding reporter molecule, chlorothiazide, in the 
supernatant of the negative control. (c) SIC of the reporter molecule in the supernatant 
after the strong binder, acetazoiamid, had been added. This experiment demonstrates 
that the assay can detect binders that do not ionize.  In other MS-based assays, these 






3.3.5 Screening for new inhibitors 
 
Because the new assay had demonstrated strong performance metrics during 
method development, we next tested a well-known target protein against a moderate 
sized library of 1200 compounds, in order to both verify that a known inhibitor could be 
readily identified and also to pan for unknown inhibitors.  A known CA binder, 
ethoxzolamide, was spiked into one set of four hundred compounds, and two other 
compound sets, each containing 400 compounds, were also prepared.  These three 
batches were used to screen for CA binders.  The compound set with the known inhibitor, 
henceforth referred to as Library B, was effective at out-competing the weak inhibitor that 
had initially been pre-loaded into the CA binding site.  The weaker binder was readily 
detectable in the assay supernatant, signaling that a compound in the library was out-
competing it for CA binding.  Figure 6A shows that in three replicate trials, the 
concentration of the weaker binder was almost three times that of the concentration of 
the control sample, where no library compounds competed for binding.  Figure 6A also 
shows results for the two other sets of four hundred compounds, which are referred to as 
Library A and Library C.  Neither one of these sets had a known CA inhibitor present.  
With no inhibitor present, each of the data points in the graphs in Figure 6A should have 
Y coordinates of approximately one.  These data points represent a ratio of the reporter 
ion’s signal in the presence and absence of the library compounds.  When no strong 
binder is present, the reporter ion’s signal should be the same, regardless of whether or 
not other compounds are present; therefore, the ratio comparing when compounds are 
present to when they are absent, should be one if no inhibitor is present.  For Library A, 
all three replicates gave such a value, near 1.0.  However, the signal for the reporter ion 
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was much higher when Library C was added.  These results indicate that some compound 
in Library C is out-competing the reporter molecule for the CA binding site and is therefore 
inhibiting CA binding.  This exciting result suggested that a new CA inhibitor was identified 
by screening just 1200 well-known compounds against a well-studied target protein.   
To further validate the results of the initial screen, and to gain more insight into the 
new inhibitor that had been identified, Library A, B, and C (Figure 6a) were divided into 
four batches with 100 compounds each (Figure 6b), and the same experiment was 
conducted as described above. The known strong binder was spiked in to Library B3 
(Figure 6b).  Ten of the 100 compound libraries indicated that no strong binding 
compounds were present; this finding emphasizes the assays power in evading false 
positives.  The only two libraries that  contained hits were Library B3, which had been 
spiked with the known strong binder, ethoxzolamide, and Library C4 (Figure 6b).  The 
high response from Library C4 was consistent with our previous experiment, and it further 
indicated that a compound in Library C4 was binding to CA and displacing the weaker-




Figure 6: Screening assay for CA binders with methoxzolamide as the reporter 
molecule.  (a) Tests conducted with 400 compound libraries.  (b) Tests with 100 
compound libraries and with pifithrin-µ.  A strong binder, ethoxzolamide, was spiked into 
Library B (400 compound set) and Library 3B (100 compound set) to verify that a 
positive response would be readily detectable when a strong binder was present.  The 
positive response for Library C and Library C4 resulted from pifithrin-µ, a CA inhibitor 
that was newly-identified in this assay.  
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After we had identified the set of 100 compounds that likely contained a new hit for 
CA, we attempted to identify the inhibitor based on structural similarity to known CA 
inhibitors.   The chemical structures of the 100 compounds in Library C4 were compared 
with well-known CA inhibitors. The compound pifithrin-µ was found to have considerable 
functional group similarities with other CA inhibitors (Figure 7). However, to our 
knowledge, pifithrin-µ has not been reported as a CA inhibitor. To confirm that pifithrin-µ 
is responsible for the competitive binding effect, another screen was carried out where 
methoxzolamide was used as the weak binder and only pifithrin-µ was added.  As 
expected, pifithrin-µ out-competed some of the weak binder that was present, at 
approximately the same degree as was observed when all 100 compounds in Library C4 
were present (Figure 6b). This experiment confirms that pifithrin-µ was responsible for 
the positive hit in the assay.  Pifithrin-µ itself is not ionizable, so it would not be detectable 
by ESI-MS in either in the positive or negative mode. This property likely explains why it 
had not previously been identified as a CA inhibitor, even though MS-based HTS assays, 
screening over 100,000 compounds had been conducted previously using CA as a target 




Figure 7: Structures of all the known CA inhibitors and the unknown CA binder pifithrin-
µ. Similar functional groups were circled in red in all the structures except dash lines 
were used on pifithrin-µ. 
Is pifithrin-µ a new CA inhibitor, or is it a false positive hit?  To answer this question, 
an inihibition assay was carried out using a standard protocol where the substrate of 
carbonic anhydrase, carbon dioxide, is transformed to carbonic acid, and this conversion 
is monitored by a change in pH of a buffered solution.  Pifithrin-µ was tested for its 
inhibitory ability, and it dramatically impacted the activity of carbonic anhydrase, even at 
low concentrations.  The IC50 was determined to be ~25 nM (Figure 8). These results 
confirm that pifithrin-µ is a newly-identified inhibitor of CA.  CA inhibitors are highly sought-
after for the development of a variety of drug products, treating diseases as broad as 
cancer to glaucoma.28,29,30,31 This new lead, therefore, expands the CA structures that 




Figure 8: The plot of % inhibition versus the log concentration of the inhibitor. IC50 





We developed a new MS-based HTS method that has two key advantages over 
existing methods: First, the assay evades false positives, since compounds that bind 
nonspecifically do not out-compete the weak binding ligand at the protein’s binding site; 
second, since the method does not detect binding ligands directly, but rather detects 
when a ligand out-competes a weaker binder, even non-ionizing compounds can be 
profiled; therefore, false negatives are mitigated as well.  The assay is rapid, screening 
400 compounds in 10 minutes, and it requires only minute quantities (pmols to nmols) of 
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target protein. After demonstrating that the assay had appropriate discriminatory power 
for three different proteins, CA was screened against a library of 1200 compounds and 
one known strong binder of the targets. We detected the spiked strong binder each time 
it was present, and none of the 1200 compounds tested gave a false positive response.  
Furthermore, a new inhibitor, pifithrin-µ, was identified; this is a surprising and exciting 
result, considering that CA inhibitors are therapeutically valuable drug targets for a 
number of diseases.  This rapid and simple assay can be implemented on a variety of 
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Chapter 4: High-Performance Ligand Fishing for Target Proteins Using Rapid 
LCMS: Finding Ligands That Exhibit a Kd in the µM Range Using Limited 
Amounts of Target Protein with No False Identifications. 
 Ligand fishing for target proteins is becoming increasingly popular due to its 
potential to expedite the time of discovery for lead compounds in the drug screening 
process. Target protein is the most valuable reagent of an assay and, thus, is an important 
limiting factor that influences the number of ligands that can be screened at once. Ligands 
with a Kd in the micromolar range are difficult to identify due to their lower affinity, and 
identification becomes more challenging when there is a limited supply of target protein. 
In this study, we developed an improved high-throughput screening (HTS) assay that 
reduces the amount of protein that is needed to screen binders by 50%. In addition, our 
previous ligand fishing HTS assays, in which d 20 µg of protein was used, were re-
characterized to identify micromolar binders in library batches, each containing 400 
compounds. The variation of the mass spectrometry ionization source can result in 
irreproducible detection of the reporter molecule in identification of potential binders with 
a reduced amount of target protein. Therefore, an internal standard was used to negate 
any such variation. In addition to lowering the consumption of proteins, this novel assay, 
similar to our previous methods, mitigates false positives by selectively identifying positive 
hits during displacement of the ligand in the binding site of interest and false negatives 







Mass spectrometry has become the preferred method of ligand fishing for target 
proteins due to its ability to perform label-free, highly selective, and sensitive high-
throughput screening.1,2,3 With ligand fishing, it can be difficult to discern tightly binding 
ligands from a library of compounds, most of which will lack the required binding motifs. 
Searching for low-affinity binders is still beneficial, because the structural information that 
can be gained from assessing the moieties that bind to the protein is useful for synthesis 
of new compounds with higher affinities or more druggable properties. Even MS-based 
techniques suffer from a high rate of false positives associated with nonspecific binding 
of compounds, which can be misleading in the drug screening process and prolong the 
discovery pipeline.  
Recently, our group developed ( as described in the chapter 3) a method for 
discovering high-affinity ligands for target proteins from ligand seas in a high-throughput 
manner, allowing us to discover ligands with a Kd in the picomolar to micromolar range 
without any false positives or false negatives. It is important that these assays be able to 
function using a low amount of target protein due to the difficulty and expense of obtaining 
pure material. Our method involves an initial incubation of the target protein with a known 
weak binder (reporter molecule) and then incubation of the protein-reporter complex with 
library compounds. If there is a stronger binder in the library, the signal for the reporter 
molecule in the assayed supernatant increases, compared to controls in which no 
compounds competes for binding. The signal increases due to displace of the reporter 
molecule by the strong binder and therefore becomes detectable. This assay identifies 
strong binders in a specific pool of ligands from batches of ligand seas that have been 
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tested in our validated HTS assays. The LC-MS method only requires one to quickly scan 
for known weak-binding reporters in a mixture of up to 400 compounds; thus, screening 
can routinely be achieved in 10 minutes per set of compounds.  
To achieve validation for HTS, it is necessary to evaluate the robustness of an 
assay by calculating the Z’ factor, a statistical parameter that was introduced by Zhang et 
al..4 It is calculated using a small number of positive and negative control samples. The 
positive control samples are prepared by spiking in a known strong binder, whereas the 
negative controls contain every compound in the positive controls except for the known 
binder. The Z’ factor must be higher than 0.5 for an assay to be considered well-validated. 
A well-validated assay has the potential to yield significantly fewer false positives when 
millions of samples are screened. A Z’ factor of less than 0.5 is considered a marginal 
assay and generates overlap between the responses of the positive and negative 
controls, which can lead to false positive identifications.  
One difficulty of this assay (chapter 3) is excessive bleeding of reporter molecule 
into the supernatant when the small amount of protein is reduced further than the 
optimized amount. This phenomenon is expected; a decreased amount of protein results 
in more dissociation of the protein-reporter molecule complex. Thus, the number of 
reporter molecules that are already bound to the target protein before being displaced by 
a strong binder is small. As a result, the mean difference in the reporter molecule 
response between positive and negative controls remains close. It is difficult to obtain an 
acceptable Z’ value (> 0.5) if the standard deviation (SD) of the responses (signal 
fluctuation) is high, as shown by the following equation:  
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The MS ionization process influences the fluctuations in signal. Internal standards can be 
used to account for this variation due to the ionization source. Decreasing the SD in the 
signals of the positive and negative controls by using internal standards is important in 
the development of a well-validated assay.  
By including an internal standard in our current study, we discovered binders with 
Kd values in the micromolar range using a small amount of target protein. We used an 
isotopically labeled reporter molecule as an internal standard to validate the assay for 
HTS and demonstrated its ability to identify a strong binder in a library with much higher 
reproducibility, allowing us to use only half the initial amount of target protein (10 µg, or 
~200 pmol) to fish out a ligand in the micromolar Kd range from a 400 compound library. 
This approach requires a smaller amount of protein for screening, which is the most 
valuable reagent in the assay, and includes all of the advantages of the previous method, 
specifically no false positives or false negatives and fast screening. These properties 
make it possible to screen for ligands with Kd values in the micromolar range, even for 
low-abundance target proteins, and reduces the time and effort required for early 





The library compounds were all FDA-approved drugs, purchased from Sigma 
Aldrich (St. Louis, MO, USA). The library was provided as a single compound per vial 
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(LOPAC1280-small scale), dissolved in DMSO at 10 mM.  Maltose-binding protein was 
purchased from My BioSource (San Diego, CA). Nitrocellulose drop dialysis membranes 
were purchased from Fisher Scientific (Houston, TX). [UL-13C12]maltose monohydrate 
was obtained from Omicron (South Bend, IN). 
4.2.2 Binding experiment  
 
Maltose-binding protein (MBP) was immobilized on N-hydroxysuccinimide (NHS)-
activated magnetic beads per the manufacturer’s protocol (PierceTM NHS-Activated 
Magnetic Beads, Thermo Scientific.Workford, IL). Briefly, after the magnetic beads were 
washed, 10 µg MBP in PBS coupling buffer (0.1 M, pH 7.4) was added to 100 µL of 
magnetic beads and slowly rocked overnight at room temperature. Drop dialysis was 
conducted on MBP (in 1.0 M Tris-HCl) before an appropriate aliquot of protein was added 
to the tube that contained the beads. After the mixture was rocked, the supernatant was 
removed and the immobilized proteins were washed with 1 mL coupling buffer. Then, 300 
µL quenching buffer (Tris-HCl, 1.0 M, pH 7.4) was added and slowly rocked for 2 hours. 
The supernatant was removed and immobilized proteins were washed with 300 µL 
washing buffer (1 M NaCl in coupling buffer), followed by the addition of 2 mL ammonium 
acetate (0.02 M, pH 8.0) incubation buffer. The supernatant was removed again and 50 
µL of 50 nM of the known weak binder, maltose, was added; the mixture was then rocked 
for 2 hours at room temperature. After removal of the supernatant, 50 µL of the 400-
compound library (300 nM) was added and rocked for 1 hour. The library compounds 
were prepared by diluting them from 10 mM to 300 nM in incubation buffer prior to 
incubation with the immobilized protein. Here, 2 µL was taken from each compound to 
prepare stock solution of library of 100 compounds with a final concentration of 100 µM. 
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When preparing the library with 400 compounds, four libraries of 100 compounds were 
combined by taking 2 µL from each library with a final concentration of 25 µM. Then 2µL 
of 25 µM compound was diluted to obtain a final concentration of 300 nM in the incubation 
buffer. After incubation, 20 µL of the supernatant was removed and 2 µL of 550 nM 
internal standard in incubation buffer, [UL-13C12]maltose monohydrate, was spiked and 
used in the LC-MS analysis.  
4.2.2 Positive and negative control experiments  
 
Positive and negative control samples were prepared following the procedure in 
the binding experiment section, except libraries with a known strong binder were spiked 
to positive control samples. For each positive control, 401 library compounds were used. 
Negative control samples contained either buffer only or 400 non-binding compounds. 
Supernatants for both controls were removed and spiked with 2 µL of 550 nM internal 
standard and used in the LC-MS analysis.   
4.2.3 LC/MS Analysis 
 
Liquid chromatography/mass spectrometry analysis was done using an Acquity 
UPLC system (Waters Corporation, Milford, MA) coupled to an Orbitrap Velos Pro mass 
spectrometer. Mobile phase A was 99.9% water with 0.1% formic acid and mobile phase 
B was 99.9% MeOH with 0.1% formic acid. For each run, 5 µL of the supernatant was 
injected onto a C18 Hypersil Gold column (Particle Size: 5 µm; 1 mm i.d X 100 mm, 175 
Å, Thermo Electron Corporation, Thermo Fisher Scientific, Pittsburgh, PA) at a flow rate 
of 50 μL/min. The following multi-step gradient was used for MBP assays: 100% solvent 
A for 3 min, then a linear increase of B to 80% in 2 min, followed by the linear increase of 
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B to 95% in the next 3 min, followed by maintaining B at 95 % in additional 30 seconds, 
after that linear decrease of B to 0 % in next 30 seconds where the column was 
maintained for another 2 min. The eluent was diverted to waste for 1 min at the beginning 
of each run to prevent salts, DMSO, and compounds that are eluted from the front end of 
the chromatogram (until the weak binder is eluted) from entering the MS source. The 
mass spectrometer was operated in the positive ion mode with a 3 kV potential on the 
ESI needle, and the capillary temperature was set at 250 ºC. Full scan MS data were 
acquired at a mass range of m/z 200-700 using the Orbitrap mass analyzer at a resolution 
of 30,000 for m/z 400. 
All peak areas were calculated using extracted ion chromatograms from the .raw 
data files for each compound. Peak areas were taken from the monoisotopic peak of 
proton or/and sodium adduct for the reporter molecule, maltose (m/z 343.1235, 
365.1054), and the internal standard, [UL-13C12] maltose monohydrate (m/z 355.1643, 
377.1462). The peak area for each extracted ion chromatogram was calculated using the 









4.3 Results and Discussion: 
 
4.3.1 Method Overview 
 
In this project, we improved on our previously developed assays through the use 
a significantly smaller amount of target protein for ligand fishing. Figure 1 illustrates a 
schematic representation of the assay development. The magnetic beads with 
immobilized target protein were first loaded with the known compound, which is referred 
to as the weak binder or reporter molecule. After this step, the supernatant was removed 
and the immobilized-protein reporter molecule complex was incubated with ligand seas, 
typically batches of 400 compounds. A strong binder (high affinity binder) in an incubated 
ligand sea then replaced the reporter molecule from the target protein. As a result, the 
concentration of the reporter molecule in the supernatant increases, compared to 
negative controls. Then the collected supernatants were spiked with an isotopically-
labeled reporter molecule as an internal standard. Next, the reporter molecule and the 
internal standard were quickly detected by LC-MS. The peak area ratio between the 
reporter molecule and the internal standard was obtained as an assay signal for each 
control. The assay was statistically validated by calculating the Z’ factor using positive 




Figure 1: Experimental workflow. The weaker binder (reporter molecule) is incubated 
with the immobilized protein, and excess reporter molecule removed.  The library 
compounds are added to the test sample.  During validation experiments, a known strong 
binder is spiked into the library, generating a positive control sample.  When present, a 
strong binder replaces the reporter molecule on the binding site of the protein, and the 
concentration of the reporter molecule increases in the supernatant relative to the 
negative control. Supernatants are collected and the internal standard (the 13C isotope of 
the reporter molecule) is spiked into each of the collected supernatants. Analysis consists 
of confirming the presence of reporter molecule and the internal standard. Peak area 
ratios of the extracted ion chromatogram between the reporter molecule and the internal 





4.3.2 Identification of transient binders with minute amount of protein  
 
To demonstrate that this workflow provides sufficient discriminatory power 
between ligand sets that do or do not have a strong binder present, several control 
experiments were completed on MBP/ligand systems. Figure 2 shows a representative 
comparison of the variation in all controls with (Figure 2a) and without (Figure 2b) internal 
standard when 10 µg of target protein was used. The calculated Z’ factors were 0.65 and 
~0.2 in the presence or absence of internal standard, respectively. These values clearly 
indicate that the internal standard is necessary to validate the assay thoroughly before 




Figure 2: Peak area variation of the weak binder (reporter molecule), maltose (Kd= 3µM, 
(a) with and (b) without internal standard, 13C-Maltose, in the samples used for Z factor 
calculations. For each sample, 10 µg of MBP was incubated with 400 non-binding 
compound, with the exception of positive controls samples, which were spiked with a 
known strong binder, maltotriose (Kd = 0.2 µM). The orange dash lines represent the 
mean value of the corresponding trials for each control.  
         Another important factor to consider is the separation band, which is defined as the 
difference in the assay signal distribution between the positive control samples and the 
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negative control samples, as explained in the introduction. The difference between the 
mean values of the controls decreases as the amount of protein is reduced. The smaller 
the amount of protein used, the less target protein-reporter molecule complex is available. 
Therefore, the amount of reporter molecule that can be replaced by a strong binder is 
smaller and the variation in concentration of the reporter molecule in the supernatant is 
negligible. When these “low reporter” samples are subjected to LC-MS analysis, the 
variation in the ion count due to the ESI source becomes more significant, which results 
in a large SD within the samples. This large SD would not be significant if the separation 
band attained statistical validation of the HTS, as shown in previous chapter in which 20 
µg of MBP was used. To reduce the large SD that is caused by the ionization fluctuation 
in the ESI source, an internal standard is added to the controls.  This allows us to obtain 
well-validated assays that can be used to investigate much larger libraries that are 
routinely encountered in real HTS. 
4.3.3 Screening of enhanced libraries  
 
To mimic real HTS, three ligand seas, each with 400 compounds, were used and 
one (library B) was spiked with a strong binder, maltotriose. The calculated peak area 
ratios of the reporter to internal standard in each library samples were divided by the 
same ratio of blank controls, in which no library compounds were added to the protein-
reporter molecule complex. Figure 3 represents the peak area ratio calculated for each 
of the samples. Figures 3a and 3b represent screens that were carried out with and 
without internal standard, respectively. Library B was spiked with a strong binder, 
maltotriose. The y-axis value of 1 was considered to be the threshold value to identify any 
ligand sea with a strong binder. Figures 3a and 3b both show high y axis values of more 
109 
 
than 1 for library B, which alone contains the strong binder. However, this conclusion 
needs to be statistically assessed to test the validity (i.e. is the strong binder in library B, 
in this case known to be maltotriose, absent from libraries A and C), as shown in Figure 
2. The Z’ factor was calculated in Figure 2 to validate the assay for use in HTS. Obtaining 
a larger Z’ factor demonstrates the strength of the assay, indicating that there is no 
overlap between negative and positive responses, even in millions of screens. On the 
other hand, a lower Z’ factor represents a lower robustness for the assay, due to overlap 
between negative and positive control responses. As shown in Figure 3b, where identical 
libraries were run in duplicate without internal standard, the SD of the detected amount 
of reporter was high compared to data from treatment with an internal standard, shown in 
Figure 3a. In addition, even though library B in trial 1 is distinguishable from libraries A 
and C (at 99.5% CL), this was not observed in trial 2. In the latter trial, a strong binder 
could thus be misidentified as a false negative. When an internal standard was used, 
however, library B in both trial 1 and 2 was distinguishable from libraries A and C (at 
99.5% CL). This study shows the feasibility of using a significantly lower amount of protein 
to fish out very low affinity ligands from ligands seas with the use of internal standards. 
There are also the additional benefits of no false positives and negatives, the ability to 
screen 400 compounds in 10 minutes, and site specific binding, all of which are inherent 




Figure 3: Peak area variation of the weak binder, maltose, to control (a) with and (b) 
without internal standard, 13C-Maltose, in libraries a, b, and c. For each sample, 10 µg of 
MBP was used and incubated with libraries containing 400 different non-binding 
compounds, with the exception of library B, which was spiked with a known strong binder, 
maltotriose. The red dotted line represents the value of 1, which characterizes the 




4.4 Conclusion:  
 
The most valuable reagent in a fishing assay is the target protein. We have used 
an internal standard to account for ion signal variation during ESI-MS and developed a 
well validated HTS assay for ligand fishing from ligand seas of binders with Kd’s in the µM 
range. It has improved upon our previously developed assays by decreasing the amount 
of target protein used. We were able to reduce the amount of protein necessary to assay 
400 library compounds by half (20 µg to 10 µg), while still obtaining an excellent Z’ factor 
(0.6) to validate the assay for HTS. Without the internal standard, the reduced amount of 
protein is only useful for obtaining a marginally validated assay with a Z’ factor of 0.2. 
After using the validated assay to screen various ligand seas, only the ligand sea that 
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Chapter 5: Future Directions towards the Automation and Screening of Protein-
Protein Interactions 
5.1 Dissertation Summary: 
 
 This dissertation describes a novel and improved MS-based High Throughput 
Screening (HTS) method to screen for drug candidates for a given protein target. Chapter 
one summarizes the execution, advantages, and limitations of the currently available MS 
based high throughput methods. Chapter two describes the development of an MS-based 
HTS method to identify the tightest-binding lead compounds for target proteins with no 
false positive identifications. Three different proteins and hundreds of non-inhibitors were 
used to demonstrate the validity of the assay; no false positive hits were identified in any 
experiment. The assay was modified to select for ligands of a particular binding affinity by 
varying the quantity of protein used (and the immobilization method), as evidenced by the 
results where inhibitors that have Ki values of 0.2 µM, 50 pM, and 700 pM were selectively 
detected. The results included in Chapter two demonstrate that this methodology 
compares favorably to traditional MS based screening methods. 
 Chapter three describes the modifications applied to the assay explained in 
Chapter two in order to increase the throughput, in addition to addressing false negative 
identifications. The method described in Chapter three dramatically increases the pace 
of library screening from 400 compounds/ hour to 400 compounds/ 10 minutes. Finally, a 
novel carbonic anhydrase inhibitor, pifithrin-µ (IC50 = 25 nM), that would have been a false 
negative in most MS-based HTS methods, was identified using the modified assay. 
Chapter four extended the work described in Chapter three by modifying the method to 
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further reduce the quantity of the protein required for the assay by 50% when screening 
for weak affinity binders. 
5.2 Future Directions: 
 
 The most challenging portion of the early drug screening process is the 
identification of a therapeutically valuable binder to a target protein. As explained in 
Chapter three, introduction of an ionizable reporter molecule to the target protein 
mitigates false positives and false negatives, thereby increasing the probability of finding 
a therapeutically valuable compound, as we discovered in the case of carbonic 
anhydrase. For our assay, immobilization of the target protein is particularly necessary to 
separate unbound compounds from the protein-ligand complex. However, immobilization 
requires several hours and confers numerous disadvantages. These limitations include 
inactivation of the target protein, incompatibility of the solid support with the 
immobilization of target protein, alteration of the binding site, and hindrance of possible 
ligand approaches to the binding site of the target. Furthermore, multiple step 
experimental approaches and manual error can alter the results. Therefore, an automated 
experimental set up that does not require target immobilization would be a promising 
approach for the advancement of our method. If a membrane filter can separate the 
unbound compounds from the complex, the immobilization step can be omitted from the 
experimental procedure. However, in our experience, the currently available membrane 
filters demonstrate poor success in filtering out unbound compounds from the protein-
ligand complex. Some common problems of this approach are the high affinity of some 
small molecules to the membrane material, and spectral overlap of leachable materials 
from membrane with the reporter molecule. Most of the commercially available 
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membranes are made of cellulose materials, which acts as hydrophobic surfaces, 
resulting in the binding of hydrophobic small molecules. If the membranes are made of 
glass fibers, the separation of unbound compounds from the complex could be a 
possibility. However, the pore sizes of commercially available glass membranes are not 
small enough to retain the protein complex. Overcoming this membrane issue is a 
necessity for the development of an automated ultra-high-throughput screening assay.  
The modulation of biological pathways by targeting protein-protein interaction 
(PPIs) opens up an exciting class of potential drug targets. One of the current projects in 
the Desaire group is focused on developing an assay to screen for inhibitors of protein-
protein interactions. Fluorescence polarization (FP),1,2,3 fluorescence resonance energy 
transfer (FRET),4,5 and surface plasmon resonance (SPR),6 and enzyme linked 
immunosorbent assays7 are some of the currently used common methods for screening 
PPI inhibitors/modulators. These assays share many limitations, including the 
requirement for extensive labeling and large amounts of proteins, and show high rates of 
false positives due to nonspecific signal. Therefore, mass spectrometry can be used as 
an alternative to traditional methods of screening for PPI inhibitors, due to increased 
sensitivity, lower sample consumptions, and label-free specificity. However, previously 
reported mass spectrometry based screening approaches for protein-protein interactions 
in cell cultures using affinity chromatography and affinity purification pull-down techniques 
require specific antibodies and purification that is often inefficient.8,9 Also, to our 
knowledge, a high throughput screening method to screen for inhibitors for protein-protein 
interactions is not currently available.10,11 To develop this novel type of assay, one protein 
is first immobilized on a solid support and allowed to form a protein-protein complex with 
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the second protein. Then, the protein complex is incubated with library compounds. The 
existence of a probable inhibitor in a particular library can be identified by monitoring for 
the presence of the released protein (from the complex) in the supernatant, compared to 
the control where no library compounds are added. One of the model protein-protein 
interactions that we are planning to utilize is the complex formed by p53, a tumor 
suppressor protein,12 and the oncoprotein murine double minute 2 (MDM2), an inhibitor 
of p53 which is analogous to human double minute 2 protein.13 Even with this PPI 
approach, a suitable membrane cut off filter could be used when there is a significant size 
difference between the two interacting proteins. If the necessary improvements are 
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